Tag Archives: SAMR

Wholly Foreign-Owned Hospital Pilot and Private Healthcare Opening

  • The “Pilot Work Plan for Expanding Opening in the Wholly Foreign-Owned Hospital Sector” (NHC, MOFCOM et al., Guowei Yizhengfa [2024] No. 36) permits wholly foreign-owned hospitals in nine provincial regions.
    国家卫生健康委、商务部等四部门《独资医院领域扩大开放试点工作方案》(国卫医政发〔2024〕36号)允许在9个省市设立外商独资医院。
  • The pilot covers Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and all of Hainan, explicitly excluding TCM institutions and the acquisition of public hospitals.
    试点范围涵盖北京、天津、上海、南京、苏州、福州、广州、深圳及海南全岛,明确排除中医类机构与并购公立医院。
  • Eligible hospitals are general, specialised or rehabilitation hospitals at tertiary level; blood-disease, psychiatric, infectious-disease and TCM hospitals are barred, and haematology is excluded from the practice scope.
    符合条件的医院类别为综合医院、专科医院、康复医院且级别为三级;禁止设立血液病、精神病、传染病、中医医院,且诊疗科目不得登记血液内科。
  • Foreign and HK/Macao/Taiwan physicians may be employed short-term, but Chinese (mainland) personnel must make up at least 50% of both management and professional staff.
    可按规定聘用外国及港澳台医师短期执业,但全院管理与卫生专业技术人员的中方(内地)人员占比均不得少于50%。
  • Approval sits with provincial health authorities (setting approval plus a five-year practice licence), with information systems connected to local regulatory platforms and data servers located in China.
    设置审批与执业登记由省级卫生健康行政部门核发(执业许可证有效期5年),信息管理系统须接入属地监管平台,服务器位于境内。
  • The plan folds into a broader “orderly expansion of opening in the medical sector” and offers foreign investors a greenfield route distinct from the previous Sino-foreign joint-venture hospital model.
    该方案属于”医疗领域有序扩大开放”整体部署,为外资提供区别于以往中外合资合作医院模式的新设独资路径。

Wholly Foreign-Owned Hospital Pilot and Private Healthcare Opening | 外资独资医院试点与社会办医扩大开放

Why this matters now

For foreign healthcare groups, China’s hospital market has long been accessible only through joint ventures or minority stakes under the Sino-foreign cooperative medical-institution framework. The late-2024 pilot to permit wholly foreign-owned hospitals changes that calculus: it creates a greenfield route for international operators to build and control a hospital on the mainland, bringing management models, clinical pathways and technology that complement the public system. The pilot is deliberately scoped — geographic, institutional and clinical guardrails are explicit — so the opportunity is real but bounded.

Market context: demand and the foreign-model case

The nine pilot regions are not arbitrary. They combine high openness, dense clusters of foreign enterprises and expatriates, and mature experience regulating foreign-funded medical institutions — exactly the conditions where demand for international-standard care is strongest. Foreign-invested hospitals are positioned to complement, not compete with, the public system: they target high-end and specialised demand, expatriate and cross-border patients, and technology- and service-model transfer that raises local standards. For provincial authorities, the pilot is also a service-environment upgrade that helps retain foreign talent and investment. The 50% mainland-personnel floor and the data-localisation duty, however, mean a foreign operator must build genuine local capability rather than merely import a brand. Realistic entrants therefore pair an international clinical franchise with a credible本地 workforce, IT and quality-system plan from day one.

The pilot framework

Issued by the National Health Commission, the Ministry of Commerce, the State Administration of Traditional Chinese Medicine and the National Disease Control and Prevention Administration (Guowei Yizhengfa [2024] No. 36, 1 November 2024), the plan authorises wholly foreign-owned hospitals in Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and all of Hainan. TCM-category institutions are excluded, and acquiring public hospitals is not permitted. The nine regions were chosen for high openness, concentrated foreign enterprises and expatriates, and mature experience in regulating foreign-funded medical institutions.

Eligibility and operating conditions

The investor must be a legal person able to bear civil liability independently, with direct or indirect experience in healthcare investment and management, and must demonstrate international-leading management, models and equipment that supplement local supply. The hospital itself:

  • may be for-profit or non-profit;
  • must be a general, specialised or rehabilitation hospital at tertiary level — psychiatric, infectious-disease, blood-disease and TCM hospitals are prohibited;
  • may not register haematology as a practice department; and
  • may not conduct high-ethical-risk activities such as organ transplantation, assisted reproductive technology, prenatal screening/diagnosis, psychiatric inpatient care, or experimental cellular tumour therapies.

Foreign, HK/Macao and Taiwan physicians may be employed short-term, but Chinese (mainland) personnel must constitute at least 50% of both the management and the professional workforce. Information systems must connect to the local medical-service supervision platform, and electronic medical records and device data must be stored on servers located in China. Hospitals meeting medical-insurance rules may apply to join the designated insurance network and are encouraged to connect with domestic and international commercial health insurance.

Approval and supervision

Setting approval and practice registration are handled at the prefecture level for initial review and then by the provincial health authority, which issues the certificate of hospital establishment and the practice licence (valid five years, renewable). The licence is brought into the medical-quality safety-management system; hospitals are encouraged to participate in accreditation, and provincial and prefecture authorities conduct ongoing monitoring and coordinated supervision. Importantly, where the pilot conflicts with prior rules, the pilot plan prevails — giving it operative priority during the trial period.

Complementary openings across the medical sector

The hospital pilot is one move in a broader, sequenced opening of the healthcare and pharmaceutical sector. Around the same period, China removed or relaxed restrictions on foreign investment in several medical and aged-care sub-sectors, and the negative list has progressively shed items that previously capped foreign-invested enterprises in healthcare. Innovative-drug and medical-device access pathways have also been streamlined, and Greater Bay Area “medtech connexion” arrangements ease cross-boundary use of approved drugs and devices for residents. Read together, these signal a directional intent to let foreign capital and expertise enter where domestic supply is constrained or where international standards add value. Foreign groups should therefore map the hospital route against this wider roadmap — a hospital licence may pair naturally with device, pharma or senior-care ventures that share the same patient and regulatory ecosystem.

Practical steps for foreign investors

  1. Select a pilot region and confirm the hospital typology (general/specialised/rehabilitation, tertiary) against the exclusions.
  2. Prepare the investment and operating case showing international management, technology and capacity complementarity.
  3. Build the mainland workforce plan that satisfies the 50% Chinese personnel threshold across both management and clinical staff.
  4. Architect the IT and data posture — local servers, platform connectivity, and a data-governance stance consistent with China’s data-security and personal-information rules.
  5. Engage the provincial health authority early for the two-step approval, and plan for the five-year licence cycle and renewal.

Related reading

The hospital pilot sits inside a wider opening of the medical and pharmaceutical sector — from innovative-drug and device access to the negative list’s removal of certain restricted sub-sectors. Foreign groups should read the hospital route together with the broader healthcare-market-access roadmap.


外资独资医院试点与社会办医扩大开放

为何当下值得关注

对境外医疗集团而言,中国医院市场长期以来只能通过合资或少数股权路径进入(即中外合资合作医疗机构框架)。2024年底推出的”允许设立外商独资医院”试点改变了这一格局:它为国际运营方提供了一条在内地自主建设并控股医院的绿地路径,用以引入与公立医院体系互补的管理模式、临床路径与技术。该试点边界清晰——地理、机构与临床层面均设有明确护栏——因此机遇真实但有限定。

市场背景:需求与外资模式的逻辑

9个试点地区并非随意选取。它们兼具对外开放程度高、外资企业与外籍人员密集、监管外资医疗机构经验成熟等特征——恰恰是国际水准医疗需求最旺盛的条件。外商独资医院定位于与公立医院体系互补而非竞争:瞄准高端与专科需求、外籍及跨境患者,并以技术与管理模式转移提升本地标准。对省级政府而言,试点也是留住外资人才与投资的营商环境升级。但中方人员不少于50%与数据本地化义务,意味着外资运营方须建设真实的本地能力,而非仅引入品牌。务实的进入者因此从第一天起就将国际临床品牌与可信的本地人才、IT与质量体系计划相配对。

试点框架

由国家卫生健康委、商务部、国家中医药局、国家疾控局联合印发(国卫医政发〔2024〕36号,2024年11月1日),方案授权在北京、天津、上海、南京、苏州、福州、广州、深圳以及海南全岛设立外商独资医院。明确排除中医类机构,且不允许并购公立医院。选取这9个省市,是因为其对外开放程度高、外资企业与外籍人员集中,且积累了丰富的外资医疗机构管理经验。

资质与运营条件

境外投资者须为能够独立承担民事责任的法人,具有直接或间接医疗卫生投资与管理经验,并能提供国际先进的管理理念、模式与服务,以及国际领先的技术与设备,以补充或改善当地医疗服务能力。医院本身须满足:

  • 经营性质可为营利性或非营利性;
  • 类别为综合医院、专科医院、康复医院且级别为三级——禁止设立精神病、传染病、血液病、中医医院;
  • 诊疗科目不得登记血液内科;
  • 不得开展人体器官移植、人类辅助生殖、产前筛查与诊断、精神科住院治疗、肿瘤细胞治疗新技术试验性治疗等伦理风险较高的诊疗活动。

可按规定聘用外国及港澳台医师短期执业,但中方(内地)人员须占全院管理与卫生专业技术人员的均不少于50%。信息管理系统须接入属地医疗服务监管平台,电子病历与医用设备等信息存储服务器须位于中国境内。符合医保规定的医院可按程序申请纳入医保定点,并鼓励对接国内外商业健康保险。

审批与监管

设置审批与执业登记由地市级卫生健康行政部门初审、省级卫生健康行政部门核发设置医疗机构批准书与医疗机构执业许可证(有效期5年,期满可续)。医院纳入医疗质量安全管理范畴,鼓励参加医院评审评价,省级与地市级部门开展动态监测与协同监管。值得注意的是,原有规定与本试点方案不符的,以本方案为准——在试点期内具有操作优先性。

医疗行业更广维度的配套开放

医院试点只是医疗与医药行业有序、分批扩大开放中的一步。同一时期,中国在多个医疗与养老子行业取消或放宽了外资准入限制,负面清单也逐步删除了此前约束医疗卫生领域外商投资企业的条目。创新药与医疗器械准入路径同步简化,粤港澳大湾区”港澳药械通”等安排也便利了居民跨境使用已获批药品与器械。综合来看,这些举措释放出允许外资与专长进入供给受限或国际标准的确能增值领域的导向性意图。外资集团因此应将医院路径置于更宏观的路线图中研判——一张医院牌照可能天然与共享同一患者与监管生态的器械、药品或养老业务协同。

外资投资者实务步骤

  1. 选定试点地区,并对照排除项确认医院类型(综合/专科/康复,三级)。
  2. 准备投资与运营方案,论证国际管理、技术与能力互补性。
  3. 构建内地人才计划,满足管理与临床中方人员均不少于50%的要求。
  4. 设计IT与数据架构——境内服务器、平台对接,以及与数据安全、个人信息保护规则一致的数据治理立场。
  5. 尽早对接省级卫生健康行政部门完成两步审批,并规划5年证照周期与续期。

延伸阅读

医院试点位于医疗与医药行业更广开放版图之中——从创新药与医疗器械准入,到负面清单取消若干受限子行业。外资集团应将医院路径与更宏观的医疗服务市场准入路线图一并研读。

Sources

  • 国家卫生健康委、商务部、国家中医药局、国家疾控局:《独资医院领域扩大开放试点工作方案》(国卫医政发〔2024〕36号)— https://www.gov.cn/zhengce/zhengceku/202411/content_6990279.htm

Medical-device import registration and the foreign-device strategy under domestic substitution (2026)

  • Imported medical devices still require NMPA registration by risk class (I/II/III), and Class II/III overseas manufacturers must register their production sites with the NMPA before any China market entry.
    进口医疗器械仍须按风险分类(一/二/三类)取得国家药监局注册;二类、三类境外生产企业须向 NMPA 登记生产场地后方可进入中国。
  • Volume-Based Procurement has expanded from high-value implants into routine consumables: the coronary-stent renewal tender opened in Tianjin on 20 May 2026 with every bidder winning, and a 29-province electrosurgical-knife alliance VBP went live on 1 July 2026.
    集中带量采购已从高值植入物扩展到常规耗材:冠脉支架第二轮接续采购 2026 年 5 月 20 日在天津开标、投标企业全部中选;覆盖 29 省的电刀省际联盟集采于 2026 年 7 月 1 日落地。
  • Domestic substitution is measurably eroding foreign share — foreign penetration in some consumable segments fell from about 45% (2020) to under 25% (2025), and peripheral-vessel balloon localisation rose from 28% (2019) to roughly 58% (2025).
    国产替代正在实质侵蚀外资份额——部分耗材外资占比从约 45%(2020)降至 2025 年不足 25%,外周血管球囊国产化率从 28%(2019)升至 2025 年约 58%。
  • Foreign device makers are answering with in-China production: ERBE’s first locally built high-frequency surgical unit (VIO S CN) received its NMPA certificate on 11 June 2026 and rolled off the line on 1 July 2026.
    外资器械企业以”在华生产”应对:爱尔博首台国产高频手术设备 VIO S CN 于 2026 年 6 月 11 日获 NMPA 注册证,7 月 1 日下线。
  • VBP rules are shifting from “lowest-price-wins” toward value-based evaluation, rewarding firms with genuine technology, scale and supply stability rather than pure cost.
    集采规则正从”唯低价”转向综合价值评价,利好具备真实技术、规模与供应稳定性的企业。
  • The practical foreign-device strategy is to register imports to hold premium segments, localise production to defend volume segments under VBP, and engage the province alliances early.
    务实的外资器械策略是:以进口注册守住高端细分,以本地化生产捍卫集采下的走量细分,并尽早介入省际联盟。

Medical-device import registration and the foreign-device strategy under domestic substitution (2026) | 2026 医疗器械进口注册与国产替代下外资器械企业策略

Overview

Medical devices sit at the intersection of tight registration control and aggressive procurement reform. For a foreign device company, market access is a two-stage problem: first clear the NMPA registration gateway (still mandatory and class-based), then survive the commercial gateway of Volume-Based Procurement, where domestic substitution has become the explicit policy direction. 2026 is a pivotal year because VBP has pushed from headline implants — stents, joints — into everyday consumables, and because the 2024 negative-list “clearing” of manufacturing restrictions makes in-China production by a wholly foreign-owned plant straightforward for the first time.

This article explains the import-registration gateway, the 2026 VBP and substitution landscape, why localisation has become the default foreign response, and the practical moves a foreign device group should plan. It is informational guidance, not regulatory or legal advice.

The import-registration gateway

Registration is risk-tiered. Devices are classified Class I (low), Class II (medium) and Class III (high). Class I devices are filed with the provincial NMPA office; Class II and III require registration with the NMPA (via the Centre for Medical Device Evaluation, CMDE). A registration dossier needs product technical requirements, type testing at an accredited laboratory, and a clinical evaluation or trial unless the device falls under an exemption catalogue. Quality-system compliance (Good Manufacturing Practice for medical devices) is inspected, and — critically for importers — overseas manufacturers of Class II/III devices must register their production site with the NMPA.

A frequent blind spot is the clinical-evaluation route. Not every Class II/III device needs a trial: where a product is comparable to an already-marketed same-species device, a literature-and-data “same-species” comparison can support trial exemption; novel or high-risk devices with no predicate still require a trial. The route choice dictates evidence cost and launch pace and should be settled at project kick-off. Imported products also need Chinese labels and package inserts; customs clearance hinges on the NMPA registration certificate as a key document.

The 2026 VBP and substitution landscape

VBP — the “集中带量采购” program that exchanges steep price cuts for committed volume — has become the dominant commercial gate for devices, and 2026 shows it reaching deeper into consumables.

Coronary stents, renewal round. On 20 May 2026 the national organisation opened the second renewal tender for coronary stents in Tianjin. Fifteen enterprises with 30 products bid, all bidders won, and 27 products were pre-selected — including upgraded new products from both foreign players (Medtronic’s “Resolute Onyx”, Abbott, Boston Scientific) and domestic leaders (MicroPort, Lepu, JW). Demand came from 4,468 medical institutions (up 86% vs the first tender) with an annual requirement of about 2.73 million stents (up 155%). Stainless-steel stents were included in the national tender for the first time at a ceiling of ¥848, while the alloy-stent ceiling was raised about 11.9% to ¥949 — a signal that rules are moderating toward value rather than pure price.

Electrosurgical knives, 29-province alliance. A Hunan-led inter-provincial alliance covering 29 provinces, municipalities and the Xinjiang Production and Construction Corps went live on 1 July 2026, with a two-year purchasing cycle and total volume above 20 million units/pieces and a market scale above ¥3.5 billion. In 17 core bidding groups, domestic brands took the lowest bid in 16 — and analysts estimate foreign share of the electrosurgical consumable market (above 50% before the tender) could fall below 30% afterward.

Broader alliance activity. The “3+N” and provincial alliances kept broadening through 2026: dural patches and indwelling needles (Tianjin-led, results published 11 March 2026), digestive-intervention snares, peripheral-vessel balloons and orthopaedic irrigation systems (Hebei-led product briefings in March 2026), plus起搏器 and peripheral micro-catheters spanning 27–29 provinces. The clear trend: VBP is becoming the normal commercial environment across the device catalogue.

Measurable substitution. The effect on foreign share is concrete. In digestive-intervention snares, foreign brands’ share fell from about 45% (2020) to under 25% (2025) as domestic players like Micro-Tech pushed hospital penetration above 70%. In peripheral-vessel constrained balloons — long monopolised by Medtronic and Abbott — localisation rose from 28% (2019) to about 58% (2025) and is expected to exceed 70% after the latest tender, with domestic leaders Lepu, Volcano (Huatai) and HeartCare (MicroPort) capturing share. Foreign brands retain an edge only in complex, high-end niches where price gaps of 3–5× still apply but where VBP’s volume logic steadily erodes the addressable market.

Why localisation is now the default response

Faced with VBP price compression and substitution pressure, an increasing number of foreign device makers are shifting from “import the finished unit” to “build it in China.” The logic is operational as much as commercial.

ERBE’s VIO S CN is the 2026 template. ERBE, the German electrosurgery leader (market share ~43.9% of high-frequency surgical-equipment tenders in Jan–May 2026), had imported its units from Germany, absorbing long shipping and customs lead times and high distribution cost. Its first China-built host, VIO S CN — developed with deep Chinese-team input on the German production system — received its NMPA registration certificate on 11 June 2026 and rolled off the line on 1 July 2026. Local production compresses logistics and import cost and sharply improves supply responsiveness, exactly the variables VBP punishes importers on.

Manufacturing is now open. The 2024 negative list cleared all manufacturing-sector foreign-access restrictions (effective 1 November 2024), so a wholly foreign-owned device manufacturing plant in China no longer faces the sector caps that once applied. Combined with theNMPA production-site registration for Class II/III, a foreign maker can stand up a China plant, register the site, and obtain domestic NMPA certificates for locally made SKUs — converting an “import” into a “domestic product” for tender purposes.

The rules now reward local players’ strengths. VBP design is moving from pure price toward comprehensive value evaluation — technical briefing, clinical argument, cost verification — which preserves reasonable margin for firms with real technology and scale. Local production is the most direct way for a foreign maker to match domestic competitors on price, lead time and supply stability while keeping original-equipment quality.

2026 policy context

  • Innovation prioritisation. The Medical Device Supervision and Administration Regulation directs that innovative devices receive priority review and approval, supporting domestic and foreign innovators alike in bringing novel products to market.
  • Manufacturing fully open. The 2024 negative list’s removal of the last manufacturing restrictions means device manufacturing welcomes wholly foreign-owned investment nationwide.
  • Opening under the 2026 action plan. The “Stabilising and Improving Foreign Investment” action plan (effective 1 July 2026) reinforces a pro-foreign-investment stance across healthcare and supports measures such as drug segmented manufacturing and expanded biotech/hospital pilots — the broader policy backdrop foreign device groups operate within.

What foreign device groups should do next

  • Map the portfolio against VBP exposure. Classify each SKU by whether it sits in a tendered category, its substitution risk, and whether it is premium/non-substitutable or volume/price-sensitive.
  • Keep importing where defensible. For high-end, clinically differentiated devices with weak domestic predicates, hold the import-registration route and protect premium positioning.
  • Localise where volume is at stake. For tendered, price-sensitive lines, stand up or contract China manufacturing, register the site with the NMPA, and obtain domestic certificates to compete on VBP terms.
  • Settle the clinical-evaluation route early. Decide same-species comparison, exemption or full trial at kick-off to fix evidence cost and timeline.
  • Engage the alliances proactively. Track province-alliance pipelines (Hebei, Tianjin “3+N”, Hunan, Guangdong, Zhejiang) and prepare technical briefings that support value-based evaluation.
  • Prepare Chinese labelling, inserts and a traceability system before launch, and treat the NMPA registration certificate as the customs-critical document.

Common pitfalls

  • Assuming registration equals access. Clearing NMPA registration is necessary but not sufficient; VBP outcome, not the certificate, often decides volume.
  • Importing into a tendered category. Finished-unit imports cannot match localised competitors on VBP price and lead time and will lose share.
  • Ignoring the production-site registration. Class II/III overseas manufacturers must register their site with the NMPA — a step easily missed when planning local production.
  • Treating VBP as pure price. Rules now weight technology and supply stability; a weak value story loses even when price is competitive.
  • Late alliance engagement. By the time a tender opens, grouping and evaluation are largely set; influencing them requires early technical briefing.

Sources

  • National Medical Products Administration (NMPA) — official portal: https://www.nmpa.gov.cn
  • 国家医疗保障局(NHSA)——集中带量采购:https://www.nhsa.gov.cn/
  • 国务院新闻办发布会介绍利用外资固稳促优政策措施 (2026-06): https://www.gov.cn/lianbo/fabu/202606/content_7074496.htm
  • 国务院《利用外资固稳促优行动方案》(2026-06): https://www.gov.cn/zhengce/zhengceku/202606/content_7072838.htm

Related reading

  • see also: Healthcare & pharma market access (NMPA) / 医疗医药准入(药监局)
  • see also: Pharma opening measures under the 2026 action plan / 医药产业开放新措施

2026 医疗器械进口注册与国产替代下外资器械企业策略

概述

医疗器械处在严格注册控制与激进采购改革的十字路口。对外资器械企业而言,市场准入是两段式问题:先越过国家药监局的注册关口(仍属强制且按类管理),再穿越集中带量采购这一商业关口——而国产替代已是明确的政策方向。2026 年是关键之年:集采从支架、关节等标志性植入物,推进到日常耗材;同时 2024 年版负面清单”清零”制造业准入限制,使外商独资器械工厂在华设厂首次变得顺理成章。

本文说明进口注册关口、2026 年集采与替代格局、为何本土化已成为外资的默认应对,以及外资器械集团应规划的务实举措。本文仅为信息参考,不构成监管或法律意见。

进口注册关口

注册按风险分类管理。器械分为第一类(低)、第二类(中)、第三类(高)。第一类向省级药监部门备案;第二类、第三类须向国家药监局(经医疗器械技术审评中心 CMDE)注册。注册资料需产品技术要求、资质实验室型检,以及临床评价或临床试验(除非属豁免目录)。质量体系(《医疗器械生产质量管理规范》)须受检,且——对进口商关键的是——二类、三类境外生产企业须向国家药监局登记其生产场地。

常见盲点是临床评价路径。并非所有二类、三类器械都需临床试验:若产品与已上市同品种器械可比,可通过文献与数据的”同品种”比对支持免于临床;无同品种可比或高风险的创新器械仍须开展临床试验。该路径选择决定证据成本与上市节奏,应在立项时即敲定。进口产品还须配中文标签与说明书;清关以国家药监局注册证为关键单证。

2026 年集采与替代格局

集中带量采购(”集采”以大幅降价换取约定采购量)已成为器械主导性商业关口,而 2026 年显示其正深入日常耗材。

冠脉支架,接续轮。 2026 年 5 月 20 日,国家组织在天津开标冠脉支架第二轮接续采购。15 家企业、30 个产品投标,投标企业全部中选,27 个产品获拟中选资格——既含外资新品(美敦力”Resolute Onyx”、雅培、波士顿科学),也含国内龙头(微创、乐普、吉威)。填报需求来自 4468 家医疗机构(较首轮增 86%),年度需求量约 273 万个(增 155%)。不锈钢支架首次纳入国家集采,最高有效申报价 848 元;合金支架上限由 848 元上调约 11.9% 至 949 元——信号是规则正从唯价向价值适度回调。

电刀,29 省联盟。 湖南牵头的省际联盟覆盖 29 个省区市及新疆生产建设兵团,于 2026 年 7 月 1 日落地,采购周期两年,总需求量超 2000 万把/片,市场规模超 35 亿元。17 个核心竞价组中,国产品牌包揽 16 组最低报价;分析估计外资电外科耗材份额(集采前超 50%)此后或降至 30% 以下。

更广的联盟活动。 “3+N”与省级联盟在 2026 年持续扩围:硬脑(脊)膜补片与留置针(天津牵头,3 月 11 日公布结果)、消化介入圈套器、外周血管约束型球囊与骨科冲洗系统(河北 3 月产品介绍)、以及覆盖 27–29 省的起搏器与外周微导管。清晰趋势:集采正成为器械目录的常态化商业环境。

可量化的替代。 对外资份额的影响很具体。消化介入圈套器领域,外资占比从约 45%(2020)降至 2025 年不足 25%,南微医学等国产将二级以上医院渗透率推过 70%。外周血管约束型球囊——长期由美敦力、雅培垄断——国产化率从 28%(2019)升至 2025 年约 58%,最新集采后有望破 70%,国产龙头乐普、惠泰、心脉抢占份额。外资仅在复杂高端细分仍具优势,但集采的量价逻辑持续压缩其可及市场。

为何本土化成为默认应对

面对集采降价与替代压力,越来越多外资器械企业正从”进口整机”转向”在华制造”。其逻辑既是商业也是运营。

爱尔博 VIO S CN 是 2026 年范本。 德国电外科龙头爱尔博(2026 年 1–5 月高频手术设备中标市占约 43.9%)此前整机自德国进口,承受漫长海运、跨境报关的高流通成本与长供货周期。其首台国产主机 VIO S CN——由中国团队深度参与、依托德国原装生产体系——于 2026 年 6 月 11 日获国家药监局注册证,7 月 1 日下线。本地生产压缩物流与进口成本,并显著提升供货响应,而这正是集采惩罚进口商的变量。

制造业现已放开。 2024 年版负面清单清空了制造业领域外资准入限制(2024 年 11 月 1 日施行),外商独资器械制造厂在华不再面临此前的行业上限。结合二类、三类器械的 NMPA 生产场地登记,外资可在中国建厂、登记场地,并为本地生产单品取得国产注册证——将”进口”转为集采意义上的”国产”。

规则现在奖励本地玩家的强项。 集采设计正从纯价格转向综合价值评价——技术介绍、临床论证、成本核验——为具备真实技术与规模的企业保留合理利润。本地生产是外资在价格、交期与供应稳定性上对标国产、同时保留原厂品质的最直接方式。

2026 年政策语境

  • 创新优先。 《医疗器械监督管理条例》明确支持创新医疗器械优先审评审批,惠及本土与外资创新者将新产品推向市场。
  • 制造业全面放开。 2024 年负面清单清除最后制造业限制,意味着器械制造在全国欢迎外商独资投资。
  • 行动方案下的开放。 《利用外资固稳促优行动方案》(2026 年 7 月 1 日落地)重申亲外资立场,并支持药品分段生产、扩大生物技术与人独资医院试点等举措——这是外资器械企业所处的更宽政策背景。

外资器械集团下一步

  • 按集采敞口映射产品组合。 将每个单品归类至是否属集采品类、替代风险高低、以及是溢价不可替还是走量价格敏感。
  • 在可守处继续进口。 对临床差异化强、国产无同品种可比的高端器械,守住进口注册路线并保护溢价定位。
  • 在走量处本土化。 对集采、价格敏感产线,自建或合同制造,向国家药监局登记场地并取得国产证,以集采条款竞争。
  • 尽早敲定临床评价路径。 立项即决定同品种比对、免于临床或临床试验,以固定证据成本与时间表。
  • 主动介入联盟。 跟踪河北、天津”3+N”、湖南、广东、浙江等省际联盟动向,准备支撑价值评价的技术介绍。
  • 上市前备好中文标签、说明书与可追溯体系,并将国家药监局注册证视为清关关键单证。

常见误读

  • 以为注册即准入。 越过国家药监局注册是必要非充分;决定销量的常是集采结果而非证书。
  • 把整机进口进集采品类。 进口整机在集采价格与交期上无法对标本土化对手,必失份额。
  • 忽视生产场地登记。 二类、三类境外生产企业须向国家药监局登记场地——规划本地生产时极易遗漏。
  • 把集采当纯价格。 规则现已权衡技术与供应稳定性;价值陈述薄弱者即便价格有竞争力也会落败。
  • 联盟介入太晚。 集采开标时分组与评价基本已定;影响它们需提前技术介绍。

来源

  • 国家药品监督管理局(NMPA)——官方门户:https://www.nmpa.gov.cn
  • 国家医疗保障局(NHSA)——集中带量采购:https://www.nhsa.gov.cn/
  • 国务院新闻办发布会介绍利用外资固稳促优政策措施(2026-06):https://www.gov.cn/lianbo/fabu/202606/content_7074496.htm
  • 国务院《利用外资固稳促优行动方案》(2026-06):https://www.gov.cn/zhengce/zhengceku/202606/content_7072838.htm

相关阅读

  • 参见:医疗医药准入(药监局) / Healthcare & pharma market access (NMPA)
  • 参见:医药产业开放新措施 / Pharma opening measures under the 2026 action plan

China’s Copyright Collective Management System (2026): What Foreign Rights Holders and Users Should Know

  • Copyright collective management lets a single licensed society exercise rights that individual rights holders cannot efficiently enforce themselves — performance, broadcasting, rental, information-network transmission and reproduction — and license users, collect royalties, and distribute them on the rights holder’s behalf.
    著作权集体管理由依法设立的集体管理组织,集中行使权利人难以自行有效行使的权利——表演权、广播权、出租权、信息网络传播权、复制权等,并以自己名义向使用者许可、收取使用费并向权利人转付。
  • Only organisations established under the Regulation on the Administration of Copyright Collective Management (State Council Decree No. 429) may conduct collective management; no other entity or individual may do so.
    只有依据《著作权集体管理条例》(国务院令第 429 号)设立的组织方可从事集体管理活动,其他任何组织和个人均不得从事。
  • A foreign or stateless rights holder can be covered in China through a mutual-representation agreement between a Chinese collective management organisation and its overseas counterpart, which must be filed with and announced by the national copyright authority.
    外国及无国籍权利人可通过中国集体管理组织与境外同类组织订立的”相互代表协议”获得覆盖,该协议须报国务院著作权管理部门备案并予以公告。
  • The licensing contract with a user cannot be exclusive, must be in writing, and is capped at two years (renewable); the organisation may not refuse a user who requests a licence on reasonable terms.
    与使用者订立的许可使用合同不得为专有许可、须以书面形式订立、期限不得超过 2 年(可续订);对以合理条件要求订立合同的,集体管理组织不得拒绝。
  • Royalties collected, after deducting management fees, must be paid in full to rights holders and may not be diverted; fee records must be kept for at least ten years and are open to inspection by rights holders and users.
    收取的使用费在提取管理费后须全部转付权利人、不得挪作他用;使用费转付记录须保存 10 年以上,权利人及使用者有权查阅。
  • The national copyright authority supervises organisations through annual audits, mandatory disclosure of fee schedules, and a 60-day deadline to investigate complaints from rights holders or users.
    国务院著作权管理部门通过年度审计、使用费收取标准公告公示以及对权利人/使用者举报 60 日内调查处理等制度实施监督。

China’s Copyright Collective Management System (2026): What Foreign Rights Holders and Users Should Know | 中国著作权集体管理制度(2026):涉外权利人与使用者须知

Why collective management exists

Many copyright rights are impractical for an individual creator or company to monitor and license one transaction at a time. Whoever owns the public-performance right to a song cannot realistically chase every café, shopping mall, radio station and streaming platform that plays it. China solves this through copyright collective management — a system in which a single licensed society, authorised by many rights holders, bundles their rights, licenses users centrally, collects royalties, and distributes them back. For a foreign-invested enterprise that either owns copyrighted works or uses music, text, software or broadcasts in its business, understanding this system is essential: it determines how you lawfully license background music, karaoke, online content, or how your own works get enforced and monetised in China.

The legal foundation

The system rests on the Regulation on the Administration of Copyright Collective Management (State Council Decree No. 429, effective 1 March 2005), issued under the Copyright Law. The regulation defines what collective management is, who may do it, how an organisation is set up, how it operates, and how it is supervised. Supplementary approval rules are maintained by the National Press and Publication Administration (which houses the National Copyright Administration, NCA). The key structural point: collective management is a closed, licensed monopoly — only organisations approved by the NCA may operate, and their business scopes must not overlap.

What rights can be collectively managed

Under the regulation, the rights that rights holders “find difficult to effectively exercise themselves” may be managed collectively. These include:

  • Performance right — public playing or singing of a work.
  • Projection/rendering right — showing a work in public by technical means.
  • Broadcasting right — wireless or wired broadcasting and rebroadcasting.
  • Rental right — renting out originals or copies of certain works.
  • Information-network transmission right — making a work available to the public over a network.
  • Reproduction right — among others that are hard to police individually.

These are precisely the rights that a foreign brand’s in-house legal team cannot practically police across thousands of venues or platforms — which is what makes collective management the practical enforcement channel.

How an organisation is established

Establishing a collective management organisation is a State-approved activity. The threshold conditions are specific:

  1. At least 50 rights holders发起设立 (as initiators).
  2. Its business scope must not cross or overlap with an already-registered organisation.
  3. It must be able to represent the relevant rights holders’ interests nationwide.
  4. It must have draft articles, a draft fee-collection standard, and a draft royalty-distribution method.

The applicant files with the NCA, which decides within 60 days whether to grant a Copyright Collective Management Licence. Within 30 days of approval, the applicant registers with the Ministry of Civil Affairs; within 30 days of registration, it files a copy of the registration certificate with the NCA, which announces the articles, fee standard and distribution method. The organisation must run its general assembly at least annually and maintain a council of no fewer than nine members.

How collective management works in practice

For a rights holder, the flow is:

  • Sign a collective management contract authorising the organisation to manage specified rights. The organisation may not refuse a qualified rights holder.
  • While the contract is in force, the rights holder generally may not itself exercise or license the contracted rights.
  • A rights holder may withdraw per the organisation’s rules; however, licences already granted to users remain valid until expiry, and the rights holder keeps entitlement to royalties from them.

For a user (say, a retailer playing music, a hotel offering video-on-demand, or a platform streaming content), the flow is:

  • The organisation must license on reasonable request and may not refuse or impose an exclusive licence.
  • The licence contract is in writing, capped at two years, renewable.
  • The user must provide usage data (titles, right-holder names, manner, quantity, time) unless the contract says otherwise; the organisation has a confidentiality duty over any trade secrets in that data.
  • The organisation must maintain a rights-information query system that both rights holders and users can consult.

Royalties and supervision

The economic safeguards are deliberately strict:

  • The organisation sets a fee-collection standard, which is announced by the NCA; royalties are then negotiated against that standard.
  • After deducting a management fee (which must decline as revenue rises), all remaining royalties must be paid to rights holders — none may be diverted.
  • The organisation must keep royalty-distribution records for at least ten years, and rights holders and users have a statutory right to inspect them.
  • Each year the organisation publishes an audited financial report.
  • The NCA supervises through on-site checks, account review, and attendance at key meetings, and must investigate complaints within 60 days. Rights holders may report refusals to license, mis-handled fees, or denied record access; users may report unlawful refusals to contract or failures to apply the announced fee standard.

What this means for foreign-invested enterprises

  • If you use copyrighted content in China — background music in stores, karaoke in F&B outlets, streaming or broadcast features in apps, or reproduction of texts/images — obtain licences through the relevant collective management organisation rather than assuming individual clearance covers public-performance or network-transmission scenarios. Keep your usage records; they are your defence against disputes and your input to royalty calculation.
  • If you own copyrights — music, literature, software, audiovisual works — you can join a Chinese collective management organisation, or, more commonly for foreign holders, be covered via a mutual-representation agreement between that organisation and your home-country society. File and confirm the agreement’s NCA备案/announcement so your coverage is recognised.
  • Plan for two-year licence cycles and budget royalties against the announced fee standards; treat the management-fee decline and full-distribution rules as your assurance that fees reach rights holders (including you, if you are one).
  • Watch the boundaries. The organisation cannot grant exclusive licences, cannot refuse reasonable requests, and cannot divert royalties. If you encounter such conduct as a user or rights holder, you have a statutory complaint route to the NCA.

Boundaries to keep in mind

Collective management covers only the rights assigned to it — it is not a blanket licence for all uses, and it does not replace direct licensing for rights outside its scope (e.g., translation, adaptation, or exclusive commercialisation you wish to control yourself). The mutual-representation route is the practical bridge for most foreign rights holders, but it depends on a valid, filed agreement. And because each organisation has a non-overlapping scope, identify the correct one for your specific right (performance, reproduction, network transmission, etc.) before engaging.


中国著作权集体管理制度(2026):涉外权利人与使用者须知

为何需要集体管理

许多著作权权利若由权利人逐笔监督与许可,在现实中几乎不可行。一首歌曲的公开表演权人,不可能逐一追查每一家咖啡馆、商场、广播电台与流媒体平台。中国的解决之道是著作权集体管理——由一家经许可的集体管理组织,获得众多权利人授权后将其权利打包,统一向使用者许可、集中收取使用费并分配回权利人。对于既可能拥有作品又可能使用音乐、文字、软件或广播内容的在华外资企业而言,理解这套制度至关重要:它决定了你如何合法取得背景音乐、卡拉 OK、线上内容的许可,也决定了你自己的作品在中国如何获得保护与变现。

法律基础

该制度建立在《著作权集体管理条例》(国务院令第 429 号,2005 年 3 月 1 日施行)之上,系依据《著作权法》制定。条例界定了集体管理的含义、主体资格、设立程序、运营规则与监督机制。补充性的审批规则由国家新闻出版署(加挂国家版权局牌子)维护。关键结构特征是:集体管理是一种封闭、经许可的专营——只有经国家版权局批准的组织方可运营,且其业务范围不得交叉、重合。

可纳入集体管理的权利

依条例,权利人”难以有效行使”的权利可由集体管理组织管理,主要包括:

  • 表演权——公开表演或演奏作品。
  • 放映权——通过技术手段公开再现作品。
  • 广播权——无线或有线方式广播及转播。
  • 出租权——出租特定作品原件或复制件。
  • 信息网络传播权——通过网络向公众提供作品。
  • 复制权——以及其他难以个别监管的权利。

这些恰恰是外资品牌自有法务团队难以在成千上万个场所或平台逐一维权的权利——这也正是集体管理成为实际维权通道的原因。

组织如何设立

设立集体管理组织属于行政许可事项,门槛明确:

  1. 发起设立的权利人不少于 50 人。
  2. 业务范围须与已登记组织不交叉、不重合。
  3. 须能在全国范围代表相关权利人利益。
  4. 须具备章程草案、使用费收取标准草案及使用费转付办法草案。

申请人向国家版权局提交材料,国家版权局自收到之日起 60 日内作出是否批准的决定;获批后 30 日内到民政部办理登记;登记证书核发后 30 日内将副本报国家版权局备案,由后者公告章程、收费标准与转付办法。组织须每年至少召开一次会员大会,理事会成员不少于 9 人。

集体管理的实际运作

对权利人而言,流程为:

  • 订立集体管理合同,授权组织管理特定权利;对符合条件的权利人,组织不得拒绝。
  • 合同有效期内,权利人一般不得自行行使或许可合同约定的权利。
  • 权利人可按章程退出;但已授予使用者的许可在期满前继续有效,权利人仍有权取得相应使用费。

对使用者(如在门店播放音乐的零售商、提供点播的酒店、流媒体平台)而言,流程为:

  • 组织必须按合理请求予以许可,不得拒绝,也不得订立专有许可。
  • 许可合同须为书面形式,期限不超过 2 年,可续订。
  • 使用者须提供使用数据(作品名称、权利人名称、使用方式、数量、时间等),合同另有约定除外;涉及商业秘密的,组织负有保密义务。
  • 组织须建立权利信息查询系统,供权利人与使用者查询。

使用费与监督

经济层面的保障十分严格:

  • 组织制定使用费收取标准,由国家版权局公告;使用费在该标准基础上协商确定。
  • 提取管理费(须随收入增加而逐步降低)后,剩余使用费须全部转付权利人,不得挪作他用。
  • 组织须编制并保存使用费转付记录至少 10 年,权利人与使用者有权查阅。
  • 组织每年须发布经审计的财务报告。
  • 国家版权局通过现场检查、账目核查、列席重要会议实施监督,并须在 60 日内调查举报事项。权利人可就拒绝许可、费用处理不当、拒绝提供记录等举报;使用者可就违法拒绝订约或未按公告标准收费等举报。

对在华外资企业的启示

  • 若你在中国境内使用受版权保护的内容——门店背景音乐、餐饮卡拉 OK、应用内的流媒体或广播功能、文字/图像复制等——应通过相关集体管理组织取得许可,而非想当然地认为个别授权已覆盖公开表演或网络传播场景。保留使用记录:既是争议抗辩依据,也是使用费计算的基础。
  • 若你拥有版权——音乐、文学、软件、视听作品——可加入中国集体管理组织;对境外权利人更常见的方式,是通过该组织与本国同类组织之间的相互代表协议获得覆盖。确认该协议已向国家版权局备案并公告,以便你的覆盖获得承认。
  • 规划 2 年许可周期,并依据公告的收费标准预算使用费;将管理费递减与全额转付规则视为费用最终到达权利人(包括你自身,若你也是权利人)的保障。
  • 注意边界。 组织不得授予专有许可、不得拒绝合理请求、不得挪用使用费。作为使用者或权利人若遇此类行为,依法可向国家版权局投诉。

须把握的边界

集体管理仅覆盖被授权给它的权利——并非对所有使用的一揽子许可,也不能替代对范围外权利(如翻译、改编或你希望亲自控制的独占商业化)的直接许可。相互代表协议是多数境外权利人最现实的桥梁,但它依赖一份有效且已备案的协议。又因各组织业务范围不重叠,在接洽前应确认针对你特定权利(表演、复制、信息网络传播等)的正确组织。

Sources

Trade Secret Protection for Foreign Firms in China: Confidentiality Measures, NDAs and Enforcement under the 2026 Rules

  • Trade secrets now expressly cover “data” and “algorithms”: the 2026 Rules bring source code, models and customer datasets inside protection.
    商业秘密现已明确涵盖”数据”与”算法”:源代码、模型与客户数据集被纳入保护范围。
  • The 2026 Trade Secret Protection Rules (SAMR Order No. 126, effective 1 June 2026) list eight reasonable confidentiality measures, including access tiers, data masking and audit logs.
    2026年《商业秘密保护规定》(市场监管总局令126号,2026年6月1日施行)列举八类合理保密措施,含权限分级、数据脱敏与操作日志留痕。
  • “Corresponding” measures—not perfect ones—suffice; they must match the information’s nature, value and carrier.
    采取”相应”保密措施即可,不要求万无一失;措施须与信息性质、价值、载体相匹配。
  • Electronic intrusion and over-right downloads are now named “improper means” for obtaining secrets.
    “电子侵入”与超权限下载被明确列为获取商业秘密的”不正当手段”。
  • Penalties run from 100,000 yuan up to 5,000,000 yuan, with criminal referral for serious cases; punitive damages of 1x–5x apply in litigation.
    行政处罚由10万元至500万元,情节严重的移送刑事;诉讼中可适用一倍以上五倍以下惩罚性赔偿。
  • A Chinese FIE should lock NDAs, access control, departure procedures and digital forensics before a leak, not after.
    外资企业应在泄密前而非泄密后,固化保密协议、访问控制、离职程序与数字取证。

Trade Secret Protection for Foreign Firms in China: Confidentiality Measures, NDAs and Enforcement under the 2026 Rules | 外资企业商业秘密保护:2026新规下的保密措施、保密协议与维权

Why Trade Secrets Matter More After 2026

For a foreign-invested enterprise, the most valuable intangible assets are often not patents or trademarks but trade secrets—source code, algorithms, formulas, customer lists, pricing and strategy. China’s framework rests on the Anti-Unfair Competition Law (revised 2025, effective 15 October 2025) and is now sharpened by the Trade Secret Protection Rules (商业秘密保护规定), SAMR Order No. 126, promulgated on 24 February 2026 and effective 1 June 2026. The Rules replace the 1995 interim provisions and, for the first time, explicitly bring “data” and “algorithms” within the protected scope of technical information.

What Counts as a Trade Secret

A trade secret is commercial information—technical or business—that is not generally known, has commercial value, and over which the right holder has taken corresponding confidentiality measures. Technical information includes structure, raw materials, formulas, processes, methods, data, algorithms, computer programs and code; business information includes ideas, management, sales, finance, plans, samples, customer information and data. Failed experiments and interim results can qualify. The “not generally known” test is judged at the time of the alleged infringement, not with hindsight.

The Eight Reasonable Measures

The 2026 Rules enumerate eight categories of reasonable confidentiality measures, giving handlers a practical checklist:

  1. confidentiality agreements (NDAs) with employees, partners and recipients;
  2. personnel management—onboarding, rotation and departure controls;
  3. physical isolation—restricted areas, locked storage;
  4. technical protection—access tiers, data masking, operation-log retention;
  5. carrier management—labelling, registration, encryption of documents and devices;
  6. device control—USB, printing, screenshot and outward-transfer restrictions;
  7. departure management—hand-back, deactivation, post-employment restraint;
  8. other measures suited to the information.

The legal test is “corresponding” (相应), not “perfect”: measures must be identifiable and proportionate to the secret’s nature, value and carrier.

Improper Means, Expanded

The Rules name specific improper means of obtaining a secret, including theft, bribery, fraud, coercion, electronic intrusion, and ultra-term or ultra-right downloading—unauthorised entry into digital office systems, servers, mail, cloud or application accounts, or exploiting vulnerabilities. They also cover disclosure or use in breach of a confidentiality obligation, inducement to infringe, and third parties who knowingly acquire, disclose or use an illicitly obtained secret. Statutory safe harbours remain: independent discovery, reverse engineering of publicly available products, and disclosure to expose illegality or protect national security.

Administrative Enforcement and Penalties

A right holder may report to the market regulation department with preliminary evidence and leads. The authority may inspect, interrogate, copy, seal and seize, and query bank accounts. Where the allegedly infringing information is substantially identical to the secret and the respondent had access, infringement may be found unless rebutted. Penalties: cease the act, confiscate unlawful gains, and a fine of 100,000 to 1,000,000 yuan; for serious cases, 1,000,000 to 5,000,000 yuan. “Serious” includes large direct loss, major disruption to the right holder’s operations, harm to national or public interest, or a repeat offence within two years. Criminal referral follows for suspected crimes.

Litigation and Punitive Damages

In court, the Supreme People’s Court’s Interpretation on Punitive Damages for IP Infringement (法释〔2026〕7号, effective 1 May 2026) lets a plaintiff seek 1x–5x damages where infringement is intentional and serious. Deliberate trade-secret misappropriation by a competitor is expressly covered. Where the defendant refuses to produce books and records without cause, the court may fix the base on the plaintiff’s claim and evidence. For a foreign firm, the practical lever is the same as for administrative action: a documented, “corresponding” confidentiality program turns a weak claim into an enforceable one.

A Pre-Leak Compliance Program for a China FIE

  • Classify secrets by value and sensitivity; label and register carriers.
  • Tier access by role; mask and log; disable high-risk outbound channels for crown-jewel data.
  • NDAs everywhere—employees, contractors, JV partners, acquirers—with clear scope and remedies.
  • Departure protocol: hand-back, access revocation, and a post-employment reminder of obligations; watch “secret-poaching” and malicious raiding.
  • Forensic readiness: retain logs and access records so a leak can be traced and proven.
  • Cross-border caution: moving a secret offshore can itself trigger data-export and important-data questions—clear it through the data-compliance gate first.

Related Reading

See our copyright and trade secrets overview (No. 31), software copyright registration (No. 183) and foreign-related dispute resolution (No. 39).


外资企业商业秘密保护:2026新规下的保密措施、保密协议与维权

为何2026年后商业秘密更重要

对外资企业而言,最有价值的无形资产往往不是专利或商标,而是商业秘密——源代码、算法、配方、客户名单、定价与战略。中国制度以《反不正当竞争法》(2025年修订,2025年10月15日施行)为基,并因《商业秘密保护规定》(市场监管总局令126号,2026年2月24日公布、2026年6月1日施行)而 sharpened。该规定取代1995年暂行办法,首次明确将“数据”与”算法”纳入技术信息的保护范围。

何为商业秘密

商业秘密是不为公众所知悉、具有商业价值、经权利人采取相应保密措施的商业信息(技术或经营信息)。技术信息含结构、原料、配方、工艺、方法、数据、算法、计算机程序、代码;经营信息含创意、管理、销售、财务、计划、样本、客户信息与数据。失败的实验与阶段性成果亦可受保护。”不为公众所知悉”以涉嫌侵权行为发生时为准,不作事后倒推。

八类合理保密措施

2026年规定列举八类合理保密措施,为企业提供实操清单:

  1. 与员工、合作伙伴、接收方签订保密协议(NDA);
  2. 人员管理——入职、轮岗、离职控制;
  3. 物理隔离——限制区域、上锁保管;
  4. 技术防护——权限分级、数据脱敏、操作日志留痕;
  5. 载体管理——标注、登记、文档与设备加密;
  6. 设备管控——U盘、打印、截屏与对外传输限制;
  7. 离职管理——交还、停用、离任后约束;
  8. 其他与信息相适应的措施。

法律标准为”相应”而非”完美”:措施须可识别,并与秘密的性质、价值、载体相称。

不正当手段的扩张

规定明确列举获取商业秘密的不正当手段,包括盗窃、贿赂、欺诈、胁迫、电子侵入、超期或超权限下载——擅自进入数字化办公系统、服务器、邮箱、云盘、应用账户,或利用漏洞攻击。亦涵盖违反保密义务披露或使用、教唆引诱侵权,以及明知系非法取得仍获取、披露、使用的第三人。法定安全港仍保留:独立研发、对公开产品的反向工程、为揭露违法或维护国家安全而披露。

行政执法与处罚

权利人可凭初步证据与线索向市场监督管理部门举报。监管机关可检查、询问、复制、查封扣押、查询银行账户。在案信息与被主张秘密实质相同且被举报人有获取条件的,可认定侵权,除非其举证反驳。处罚:责令停止、没收违法所得,并处10万元至100万元罚款;情节严重的处100万元至500万元。情节严重者含权利人直接损失较大、对其生产经营造成重大不利影响、危害国家或公共利益,或两年内再犯。涉嫌犯罪的移送刑事。

诉讼与惩罚性赔偿

在司法中,最高人民法院《关于审理侵害知识产权民事纠纷案件适用惩罚性赔偿的解释》(法释〔2026〕7号,2026年5月1日施行)允许原告在故意且情节严重时请求一倍以上五倍以下赔偿。竞争对手故意窃取商业秘密明确覆盖在内。被告无正当理由拒不提供账册的,法院可依据原告诉请与证据确定基数。对外资企业,抓手与行政维权相同:有文档、有”相应”措施的保密体系,能把薄弱主张变为可执行权利。

外资企业的泄密前合规方案

  • 按价值与敏感度分级秘密,标注并登记载体。
  • 按角色分级权限,脱敏并留痕;对核心数据禁用高风险外传通道。
  • 处处签NDA——员工、承包商、合资伙伴、收购方——明确范围与救济。
  • 离职程序:交还、停用权限、提醒离任后义务;警惕”携密跳槽”与恶意挖角。
  • 取证准备:留存日志与访问记录,使泄密可回溯、可证明。
  • 跨境审慎:将秘密传出境外本身可能触发数据出境与重要数据问题——先经数据合规闸门。

延伸阅读

可参阅本站著作权与商业秘密总览(编号31)、软件著作权登记(编号183)与涉外争议解决(编号39)。

Sources

Franchising in China Gets a Judicial Roadmap: SPC’s 2026 Typical Cases for Foreign Brands

  • On 12 August 2026 the Supreme People’s Court released seven typical cases on commercial franchising (jia meng lian suo), clarifying how courts characterise franchise relationships, protect franchisees and sanction franchisor misconduct.
    2026年8月12日,最高人民法院发布7件商业特许经营典型案例,明确了法院如何认定特许经营法律关系、保护被特许人权益并规制特许人违法行为。
  • Courts apply a substance-over-form test: split or disguised contracts that together exhibit the hallmarks of franchising — licensed business resources, a unified business model and payment of fees — will be treated as franchise agreements.
    法院采取穿透实质的认定原则:即使合同被拆分或包装,只要共同具备”许可经营资源、统一经营模式、支付特许经营费用”三大特征,即认定成立特许经营关系。
  • Franchisees enjoy a statutory “cooling-off” right: they may unilaterally rescind the contract within a reasonable period before the licensed resources are actually used, even without an express contract clause.
    被特许人享有法定”冷静期”单方解除权:在经营资源尚未被实际利用的合理期限内,即使合同未明确约定,也可以单方解除合同。
  • A franchisor that engages in false advertising to induce the franchisee loses the contract on fraud grounds; unqualified individuals and entities that grant franchises face void or invalid contracts.
    特许人以虚假宣传诱使被特许人订立合同的,构成欺诈、合同可撤销;不具备特许人法定资格的主体签订的特许经营合同被认定无效。
  • Franchisors operating without the “two outlets, one year” track record can be penalised by commerce authorities, and the courts will uphold those administrative penalties.
    特许人不具备”两店一年”条件违规开展特许经营的,商务主管部门可予以行政处罚,人民法院依法支持。
  • For foreign brands entering China, the case law sets a compliance benchmark for franchise documentation, disclosure, cooling-off clauses and administrative filing — and signals tougher judicial scrutiny of “routine franchising” traps.
    对入华外资品牌而言,该批案例为加盟合同文本、信息披露、冷静期条款与行政备案树立了合规基准,也预示着对”套路加盟”更严格的司法审查。
  • Foreign franchisors should also map franchise exposure onto trademark law: brand resources, trade secrets and licensing terms sit at the core of what courts examine.
    外资特许人还须将加盟业务与商标法规则对接:商标资源、商业秘密与许可条款正是法院审查的核心。

Franchising in China Gets a Judicial Roadmap: SPC’s 2026 Typical Cases for Foreign Brands | 中国特许经营获司法路线图:最高法2026年典型案例对外资品牌的启示

Why this matters now

Commercial franchising — the “jiameng lian suo” model used by restaurants, retail, hotels, education and quick-service brands — has grown rapidly in China, and so have its disputes. On 12 August 2026 the Supreme People’s Court (SPC) released seven typical cases on commercial franchising, published through the court’s official channels and covered by Xinhua and other state media. For foreign brands that license their trademarks and business systems to Chinese franchisees, the release is a practical compliance readout: it shows how Chinese courts will characterise a franchise deal, what obligations sit on the franchisor, and where the enforcement risk concentrates. The cases also matter because China’s franchise market is one of the few in Asia where brand licensing at scale is subject to both the Commercial Franchise Administration Regulations and increasingly active judicial interpretation.

What the typical cases establish

The seven cases address four clusters of issues. First, contract characterisation: a company that signed a “service agreement” plus a “project logo use agreement” to avoid the franchise label still had the relationship re-characterised as a franchise because the contracts together gave the franchisee the use of business resources under a unified model for a fee. Second, franchisee protection: a franchisee who paid fees but had not yet used the business resources could exercise the statutory cooling-off right and rescind the contract, entitling them to a refund. Third, franchisor obligations: a franchisor that engaged in false advertising to induce a franchisee was found to have committed fraud, so the contract could be rescinded; a franchisor whose filing qualification was revoked mid-contract was vulnerable to termination; and an individual or entity without franchisor qualifications could not grant valid franchises. Fourth, enforcement: franchisors without the “two outlets, one year” requirement were penalised by commerce authorities, and the courts upheld the penalties; fraud and pyramid-like conduct in the franchise space was channelled into criminal liability where elements were met.

What this means for foreign franchisors

For a foreign trademark owner entering China through a master franchise or joint-venture franchise structure, the cases carry several operational lessons. Documentation matters: the more your contracts package themselves as technology services or brand-use licenses, the more likely a court will look through the form and apply franchise law anyway — so draft for the franchise regime from the start. Disclosure discipline matters: China’s franchise regulations require disclosure of registered trademarks, business model and related information before signing; the new cases reinforce that non-disclosure and over-promotion are not just administrative risks but contract risks. Cooling-off design matters: because the statutory right exists even without a clause, franchise systems should budget for early exits before the franchisee actually starts using the brand. Finally, qualification checks matter: before granting a franchise, verify the franchisee-facing entity structure, and ensure the “two outlets, one year” record and the Ministry of Commerce filing are genuinely in place, because both are now judicially tested.

Practical steps for foreign brands

  1. Audit your franchise documents. Review franchise agreements, disclosure statements and marketing materials against the substance-over-form test, and decide explicitly whether to operate under the franchise regime or another model.
  2. Reinforce disclosure. Update the disclosure document to reflect the latest trademark registrations, royalties and financial projections; keep a dated record of delivery to each franchisee.
  3. Handle the cooling-off window. Set procedures to process early rescission claims within the “not yet used” window, including refund mechanics and brand-asset recovery.
  4. Verify qualifications. Confirm the franchisor entity’s “two outlets, one year” experience and its Ministry of Commerce filing; document both before signing new franchisees.
  5. Train sales staff. Ensure marketing teams avoid absolute promises about profitability and success, since over-promotion can convert an administrative case into a fraud rescission.
  6. Coordinate IP and dispute teams. Keep trademark and trade-secret evidence ready, because in disputes the courts examine the licensed resources first; integrate franchise case law into your China dispute playbook.

Risks and compliance notes

The judicial signal is stricter than before: courts will pierce contract form, uphold franchisee rescissions, and back administrative penalties. Foreign franchisors should treat the “two outlets, one year” rule and the filing obligation as structural, not clerical. If a brand is expanding through area development agreements or sub-franchising, confirm that liability allocation between the foreign licensor and the Chinese master franchisee is clear, because in substance-over-form review the foreign brand’s trademarks are usually the core licensed resource. Finally, cross-border licensing itself touches tax withholding and IP registration; the franchise contract’s fee structure should be reviewed alongside trademark licence recordation to keep the whole structure consistent.


中国特许经营获司法路线图:最高法2026年典型案例对外资品牌的启示

为什么当下重要

商业特许经营——餐饮、零售、酒店、教育培训与快餐品牌普遍采用的”加盟连锁”模式——在中国增长迅速,纠纷也随之增多。2026年8月12日,最高人民法院发布7件商业特许经营典型案例,通过法院官方渠道发布,新华社等中央媒体广泛报道。对向中国加盟商许可商标与经营体系的境外品牌而言,该批案例是一次实用的合规读本:它展示了中国法院将如何认定加盟交易、特许人承担哪些义务、执法风险集中在何处。案例之所以重要,还因为中国是亚洲少数几个规模化品牌授权既受《商业特许经营管理条例》约束、又面临日益活跃的司法解释的市场之一。

典型案例确立了什么

7件案例围绕四组问题展开。一是合同定性:某公司签订《服务协议书》加《项目标识使用协议》以规避加盟标签,但由于合同共同赋予加盟商在统一模式下使用经营资源并支付对价,仍被重新认定为特许经营关系。二是被特许人保护:已付费但尚未实际使用经营资源的被特许人可以行使法定”冷静期”解除权并解除合同、获得退款。三是特许人义务:以虚假宣传诱使加盟商签约的特许人被认定构成欺诈、合同可撤销;合同履行期间备案资格被撤销的特许人更易被解除合同;不具备特许人资格的主体不能签订有效加盟合同。四是执法衔接:不具备”两店一年”条件的特许人被商务主管部门处罚,法院予以支持;加盟领域构成诈骗、传销要件的,移送刑事责任追究。

对外资特许人的意义

对外国商标权人通过主加盟或合资加盟结构进入中国而言,该批案例带来若干操作性启示。文件文本很重要:合同越是将自己包装成技术服务或品牌使用许可,法院越可能穿透形式、仍然适用加盟法规——因此应从设计之初就按特许经营体制起草。信息披露纪律很重要:中国加盟法规要求在签约前披露注册商标、经营模式及相关信息;新案例强化了”不披露与过度宣传不仅是行政风险,更是合同风险”。冷静期设计很重要:由于即使无条款约定也存在法定权利,加盟体系应为加盟商真正开始使用品牌之前的早期退出预留预算。资格核查很重要:授予加盟权前,应核验面向加盟商的实体结构,并确保”两店一年”业绩与商务部备案真实到位——因为二者现在都经受司法检验。

外资品牌的操作步骤

  1. 审计加盟文件。 对照”穿透实质”测试审查加盟协议、信息披露书与营销材料,并明确决定是按特许经营体制运营还是采用其他模式。
  2. 强化信息披露。 更新披露文件以反映最新商标注册、特许费与财务预测;留存向每位加盟商交付披露文件的带日期记录。
  3. 处理冷静期窗口。 建立程序,在”尚未实际使用”窗口内处理早期解约请求,包括退款机制与品牌资产回收。
  4. 核验资质。 确认特许人实体的”两店一年”经验与商务部备案;在签约新加盟商前将二者文件化。
  5. 培训销售团队。 确保营销团队避免对盈利能力与成功作出绝对承诺,因为过度宣传可能把行政案件变成欺诈撤销案件。
  6. 协同知识产权与争议团队。 准备好商标与商业秘密证据,因为争议中法院首先审查许可的经营资源;将加盟案例法纳入中国争议应对手册。

风险与合规提示

此次司法信号比以往更严:法院将穿透合同形式、支持被特许人解除合同、并支持行政处罚。外资特许人应把”两店一年”规则与备案义务视为结构性要求而非事务性要求。如果品牌正通过区域开发协议或再加盟扩张,应确认外国许可人与中国主加盟商之间的责任分配清晰,因为在穿透实质审查中,外资品牌的商标通常正是被许可的核心资源。最后,跨境许可本身还涉及预提税与知识产权备案;加盟合同费用结构应与商标许可备案一并审查,以保持整体结构一致。

Sources

Registering a Trademark in China for a Foreign Brand: CNIPA National Filing vs the Madrid Route (2026)

  • A foreign applicant without a business domicile in China must appoint a legally established Chinese trademark agency; only foreign nationals habitually resident in China may file directly.
    在中国无营业场所的外国申请人须委托依法设立的中国商标代理机构;仅经常居所在中国的外籍人士可自行办理。
  • China is first-to-file: filing both the Latin mark and a Chinese-character version early prevents squatter capture of the transliteration.
    中国实行申请在先:尽早同时注册拉丁商标与中文译名,可防止抢注者攫取音译名称。
  • Two routes exist — a direct CNIPA national filing (flexible subclasses, ~7–12 months) and a Madrid designation (centralised, but needs a local agent for refusals).
    两条路径并存——CNIPA单国直报(子类灵活、约7–12个月)与马德里指定(集中管理,但驳回须本地代理应对)。
  • CNIPA’s 17 March 2026 guidance tightened Madrid document-consistency checks and notification routing, raising the risk of missed refusal deadlines without a local monitor.
    商标局2026年3月17日指引收紧马德里文件一致性审查与通知送达,若无本地监测代理,易错过失权期限。
  • Since 1 January 2022 CNIPA issues electronic certificates only; record the mark with Customs for enforcement and takedowns.
    自2022年1月1日起CNIPA仅发电子注册证;为维权与下架应在中国海关做备案。
  • Practical step: clear the mark, file Latin + Chinese together via a Chinese agent, watch the Gazette, and record with Customs for enforcement.

实操建议:先检索,经中国代理同时提交拉丁与中文商标,监测公告,并向海关备案以维权。

Registering a Trademark in China for a Foreign Brand: CNIPA National Filing vs the Madrid Route (2026) | 外国品牌在华商标注册实务:CNIPA直报与马德里指定(2026路径)

For a foreign brand entering China, trademark protection is the single most litigation-prone gap. China follows a first-to-file system: the first to file generally wins, regardless of prior use abroad. The China National Intellectual Property Administration (CNIPA) and the Madrid System both offer valid routes, but they behave differently once examination begins.

Who can file, and how

A foreign applicant without a business domicile in China must entrust a legally established Chinese trademark agency to handle filing and other trademark matters — this is a hard gate under the *Trademark Law*. A foreign national with habitual residence in China may file in person or online at the trademark registration hall. CNIPA’s 2026 guidance for foreign applicants reiterates these rules and points to the approved agency list. A wholly-owned China branch of a foreign enterprise is treated as a Chinese enterprise, not the foreign parent’s domicile.

CNIPA national filing

A direct CNIPA filing lets the applicant pick exact goods/services under China’s Nice-based classification and tailor the specification to local subclass practice — usually more flexible than Madrid for must-win markets. Typical flow: clearance search → prepare the mark and specification → the Chinese agent files → formal examination (~1 month) → substantive examination (~6–8 months) → publication for three months → registration and an electronic certificate (paper certificates were abolished on 1 January 2022). Smooth cases often take about 7–12 months. Because China is first-to-file, filing both the Latin word mark and a Chinese-character version upfront avoids a squatter grabbing the transliteration.

The Madrid route

A Madrid designation of China is convenient for rolling out a global portfolio from a home application/registration, with centralised renewals. But two 2026 shifts matter. First, CNIPA’s 17 March 2026 guidance tightened documentary-consistency checks between the Madrid specification and the international registration, and adjusted how notifications (including provisional refusals) are served — increasing the risk that an applicant relying only on the WIPO chain misses a deadline. Second, transformation of a refused/cancelled designation into a direct CNIPA filing now demands stricter consistency proof. The practical safeguard: regardless of route, appoint a qualified Chinese agent to monitor CNIPA and answer refusals.

Enforcement and maintenance

After registration, record the mark with China Customs for border enforcement and platform takedowns. Renewals and use-evidence matter: non-use cancellation allows a third party to cancel a registered mark after three years of non-use, so keep evidence of genuine use in China. Foreign brands should also watch the Gazette during the three-month opposition window and be ready with evidence.

Practical steps

  1. Search first. Clear the Latin and Chinese versions in the CNIPA database before filing.
  2. Appoint a Chinese agent. Mandatory for foreign applicants without a China domicile.
  3. File both forms. Latin + Chinese-character mark together to pre-empt squatters.
  4. Pick the route by need. Must-win China market → national filing; global rollout → Madrid with a local monitor.
  5. Protect and maintain. Customs recordation, renewal discipline, and use evidence against non-use cancellation.

外国品牌在华商标注册实务:CNIPA直报与马德里指定(2026路径)

对外国品牌进入中国而言,商标保护是最易引发诉讼的缺口。中国实行申请在先原则:一般先申请者获胜,不论境外是否先使用。国家知识产权局(CNIPA)与马德里体系都提供有效路径,但进入审查后行为不同。

谁可申请、如何申请

在中国无营业场所的外国申请人须委托依法设立的中国商标代理机构办理申请及其他商标事务——这是《商标法》下的硬性门槛。经常居所在中国的外籍人士可亲自或在线到商标注册大厅办理。CNIPA 2026年外国申请人指引重申了这些规则并指向已公示的代理机构名单。外国企业的在华全资子公司被视为中国企业,而非外国母公司的营业场所。

CNIPA单国直报

CNIPA单国直报可让申请人按中国尼斯分类选定具体商品/服务,并贴合本地子类实践裁剪范围——对”必争市场”通常比马德里更灵活。典型流程:检索→准备图样与范围→中国代理提交→形式审查(约1个月)→实质审查(约6–8个月)→三个月初审公告→核准注册并下发电子注册证(2022年1月1日起废止纸质证)。顺畅案件通常约7–12个月。因中国申请在先,同时注册拉丁文字商标与中文译名可防止抢注者攫取音译名。

马德里路径

通过马德里指定中国,便于以本国基础申请/注册一次性铺开全球组合、集中续展。但2026年有两项变化值得注意。其一,CNIPA2026年3月17日指引收紧了马德里指定规格与国际注册的一致性审查,并调整了通知(含临时驳回)的送达方式,增加了仅依赖WIPO链路者错过失权期限的风险。其二,被驳回/注销的马德里指定转为CNIPA直报,现要求更严格的一致性证明。实务保障是:无论哪条路径,都委任合格中国代理监测CNIPA并应对驳回。

维权与维持

注册后应向中国海关备案,用于边境保护与平台下架。续展与使用证据很关键:连续三年不使用可被他人申请撤销,须保留在华真实使用证据。外国品牌还应在三个月异议期内监测商标公告,并备妥证据。

实操步骤

  1. 先检索。 提交前在CNIPA库检索拉丁与中文版本。
  2. 委任中国代理。 无中国住所的外国申请人强制要求。
  3. 双形态同报。 拉丁与中文商标一并提交,先发制人防抢注。
  4. 按需求选型。 必争中国市场→单国直报;全球铺开→马德里+本地监测。
  5. 保护与维持。 海关备案、续展纪律,以及应对不使用撤销的使用证据。

Practitioner Quick Reference

  • Agent is mandatory: no China domicile → appoint a Chinese trademark agency; only habitual residents file directly.
    代理强制:无中国住所须委中国商标代理;仅经常居所者自行办理。
  • File Latin + Chinese: first-to-file rewards early dual-form filing against squatters.
    拉丁与中文同报:申请在先,尽早双形态提交以防抢注。
  • CNIPA vs Madrid: national filing = flexible subclasses; Madrid = centralised but needs local agent for refusals.
    CNIPA对马德里:单国=子类灵活;马德里=集中但驳回须本地代理。
  • E-cert only since 2022: keep the electronic certificate for takedowns and court filings.
    2022年起仅电子证:留存电子注册证用于下架与诉讼。
  • Customs recordation: register the mark with China Customs for border enforcement.
    海关备案:向中国海关备案以边境维权。

Common Pitfalls

  • Skipping the Chinese mark: a squatter grabs the transliteration while you hold only the Latin mark.
    漏报中文商标:你只持拉丁商标时,抢注者攫取音译名。
  • Relying on WIPO only: Madrid notification routing changes (Mar 2026) risk missed refusal deadlines.
    只靠WIPO:马德里通知送达变化(2026年3月)易错过失权期限。
  • Ignoring use evidence: three years of non-use invites cancellation by a third party.
    忽视使用证据:连续三年不使用可被他人撤销。

2026 Watchlist

  • Madrid guidance enforcement: watch how CNIPA applies the 17 March 2026 document-consistency checks.
    马德里指引执行:关注CNIPA如何适用2026年3月17日文件一致性审查。
  • Examination standards: revised trademark examination/adjudication standards may publish.
    审查审理标准:修订的商标审查审理标准或出台。
  • Customs convenience: border recordation and takedown procedures may be streamlined.
    海关便利化:边境备案与下架流程或进一步简化。

Key Figures

  • First-to-file: China grants the mark to the first applicant, not the first user.
    申请在先:中国将商标授予先申请人,而非先使用人。
  • 3 months: the opposition window after publication.
    3个月:初审公告后的异议期。
  • 7–12 months: typical smooth timeframe for a national CNIPA registration.
    7–12个月:CNIPA单国注册顺畅案件的一般周期。
  • Since 2022: CNIPA issues electronic certificates only.
    2022年起:CNIPA仅发电子注册证。
  • Madrid in 2026: 116 members covering 132 economies make it a centralised global filing route.
    2026年马德里:116个成员覆盖132个经济体,是集中式全球申请路径。

Sources

Madrid Protocol and Trademark Licensing in China: Protecting Foreign Brands

  • Under the Madrid System, a foreign brand with a Chinese base mark can file one international application designating many members, instead of filing separately in each jurisdiction.
    依马德里体系,在中国拥有基础商标的外国品牌可提交一件国际申请指定多个成员,无需在各法域分别申请。
  • The international application must be based on a China trademark that is already registered or at least applied for and accepted — and its scope cannot exceed the base mark’s goods and services.
    国际申请须以已注册或至少已申请并获受理的中国商标为基础,且范围不得超出基础商标的指定商品/服务。
  • The “central attack” rule means that if the Chinese base mark is cancelled, invalidated or not renewed within five years, the entire international registration fails across all designated members.
    “中心打击”原则意味着若中国基础商标在五年内被撤销、无效或未续展,其国际注册在所有指定成员一并失效。
  • Licensing a registered mark to a Chinese joint-venture partner or distributor requires a recordal with the trademark office to be enforceable against third parties.
    将注册商标许可给中国合资伙伴或分销商须向商标主管机关备案,方可对抗第三人。
  • China offers a 2025 fast-review channel for Madrid applications where overseas signing, exhibition, brand licensing or overseas hijacking creates urgent need.
    中国为因海外签约、参展、品牌授权或已遭海外抢注而确有急需的马德里申请提供 2025 年快速审查通道。

Madrid Protocol and Trademark Licensing in China: Protecting Foreign Brands | 马德里体系在华延伸与商标许可:外资品牌保护路径

Why this matters now

For a foreign brand entering China, trademark protection is the first line of defence against copycats, and increasingly against wholly-owned local imitators. Two instruments matter most: the Madrid System for building a multi-country portfolio efficiently, and the trademark licence recordal for controlling how a local partner uses the mark. Both are mediated in China by the China National Intellectual Property Administration (CNIPA), which administers the *Measures for the Implementation of Madrid International Registration of Marks* and the recordal of licence contracts. This article explains how a foreign brand should use each.

The Madrid System: one filing, many markets

The Madrid System — governed by the Madrid Agreement and the Madrid Protocol — lets a trademark owner in a member country file a single international application through its home IP office (in China, CNIPA) designating any number of member economies. For a foreign brand already operating in China, the practical route is usually the reverse: a China-incorporated entity uses its Chinese base mark as the foundation for an international registration that extends protection outward.

Key mechanics under CNIPA’s implementation measures:

  • Eligibility. The applicant must have a genuine effective business establishment, domicile, or nationality in China. A foreign brand typically qualifies through its China subsidiary.
  • Base-mark requirement. The international application must be based on a mark already registered with CNIPA or at least applied for and accepted. The goods/services of the international registration cannot exceed those of the base mark. If the base mark is cancelled within five years, the international registration is vulnerable — the “central attack” risk.
  • Filing channels. Applications are submitted electronically via CNIPA’s online service system, which interfaces with WIPO; paper filing remains available. The applicant uploads the Chinese application form plus the English/French MM2 form, proof of eligibility, and the mark specimen.
  • Substantive review by each member. Madrid streamlines the *filing*, not the *substance*: each designated member examines under its own law. A member has 12 months (Agreement) or 18 months (Protocol) to refuse; silence means protection is granted.

The central-attack risk and how to manage it

The “central attack” (中心打击) principle is the Madrid System’s defining weakness: if the base mark is cancelled, invalidated or not renewed within five years of the international registration, the international registration — and therefore protection in every designated member — lapses, unless converted into national applications in those members (possible within three months under the Protocol).

Mitigations for a foreign brand:

  • Stabilise the base mark first. File and secure the China registration, ideally use it in commerce, and renew on time, before leaning heavily on Madrid extensions.
  • Use the 2025 fast-review channel where there is urgent need — overseas signing, exhibition, brand licensing, or actual overseas hijacking. CNIPA’s *Guidance on Fast Review of Madrid International Registration Applications* lets the applicant file a paper request with evidence of the urgent reason.
  • Keep a parallel national filing in the most critical markets as a fallback, so a base-mark problem does not collapse the whole portfolio.

Trademark licensing in China

Beyond registration, a foreign brand often needs a Chinese partner — a joint venture, manufacturer or distributor — to use the mark. Chinese trademark law treats the licensor’s recordal of the licence contract with CNIPA as the step that makes the licence effective against third parties.

What to know:

  • Recordal is advisable, not optional in practice. An unrecorded licence is harder to enforce against infringers and complicates the licensee’s own defences. CNIPA maintains the recordal, and the *Measures* provide for it.
  • Quality control is the licence’s lifeblood. Chinese law requires the licensor to supervise the licensee’s product quality; failure to exercise control can, in egregious cases, lead to cancellation of the registered mark on the ground of becoming a generic or non-used mark. The licence contract should build in audit rights.
  • Scope and term. Define the licensed goods/services precisely (within the registration), the territory (typically mainland China), the term, royalties, and what happens on termination — including recall of labelled stock and destruction of tooling.
  • Cross-border dimension. Where the licensee will export goods bearing the mark, coordinate the Madrid/ national registrations in the export markets so the licensee’s shipments do not infringe a third party or lapse for non-use.

Putting the two together

A disciplined foreign brand approach:

  1. Secure a solid China registration as the base mark (and use it).
  2. Extend outward via Madrid where multi-country coverage is needed, watching the five-year central-attack window.
  3. Where a local partner uses the mark, execute and record the licence, with quality-control and termination clauses.
  4. Align the licence’s export plans with the overseas registrations so the supply chain is clean end to end.

马德里体系在华延伸与商标许可:外资品牌保护路径

为何此刻值得关注

对外国品牌进入中国,商标保护是防御仿冒的第一道防线,且日益针对全资本地仿冒者。两类工具最为关键:马德里体系用于高效搭建多国组合,商标许可备案用于管控本地伙伴如何使用商标。两者在中国均由国家级知识产权主管部门(CNIPA,国家知识产权局)经办,其施行《马德里商标国际注册实施办法》并办理许可合同备案。本文解释外国品牌应如何运用二者。

马德里体系:一次申请,多个市场

马德里体系——由《马德里协定》与《马德里议定书》规范——允许成员国的商标权人在其本国 IP office(在中国为 CNIPA)提交一件国际申请,指定任意数量的成员经济体。对已在中国运营的外国品牌,实务路径通常相反:中国法人以其中国基础商标为根基,通过国际注册将保护向外延伸。

依 CNIPA 实施办法的关键机制:

  • 资格。申请人须在中国有真实有效的工商营业场所、住所或国籍。外国品牌通常通过其在华子公司取得资格。
  • 基础商标要求。国际申请须以已向 CNIPA 注册或至少已申请并获受理的商标为基础。国际注册的指定商品/服务不得超出基础商标范围。若基础商标在五年内被撤销,国际注册即面临风险——即”中心打击”风险。
  • 申请渠道。申请经 CNIPA 网上服务系统提交,该系统与 WIPO 对接;仍可纸件申请。申请人上传中文申请书及英文/法文 MM2 表、资格证明与商标图样。
  • 各成员实质审查。马德里简化的是*申请*而非*实质*:每个指定成员依本国法律审查。成员有 12 个月(协定)或 18 个月(议定书)予以驳回;沉默即视为给予保护。

中心打击风险及应对

“中心打击”(中心打击)原则是马德里体系的特征性弱点:若基础商标在国际注册之日起五年内被撤销、无效或未续展,该国际注册——亦即每个指定成员的保护——一并失效,除非在这些成员转为国家申请(议定书下三个月内可行)。

对外国品牌的缓释措施:

  • 先稳定基础商标。在重度依赖马德里延伸前,先在中国注册并取得权利、尽量实际使用并按时续展。
  • 利用 2025 年快速审查通道。确有急需——海外签约、参展、品牌授权或已遭海外抢注——时可用。CNIPA《马德里商标国际注册申请快速审查办理指南》允许申请人提交纸件请求并附加快审查事由证据。
  • 在关键市场保留平行国家申请作为兜底,使基础商标问题不致拖垮整个组合。

中国的商标许可

除注册外,外国品牌常需中国伙伴——合资企业、制造方或分销商——使用其商标。中国商标法将许可人与商标主管机关备案许可合同视为使许可对抗第三人的步骤。

须知:

  • 备案实为必要而非可选。未备案许可难以对抗侵权人,并使被许可人自身抗辩复杂化。CNIPA 办理备案,《实施办法》予以规定。
  • 质量控制是许可的生命线。中国法律要求许可人监督被许可人产品质量;极端情况下疏于控制可致注册商标因泛化或未使用而被撤销。许可合同应嵌入审计权。
  • 范围与期限。精确界定许可的商品/服务(在注册范围内)、地域(通常中国大陆)、期限、许可费及终止后安排——包括带标库存回收与模具销毁。
  • 跨境维度。若被许可人将出口带标货物,须协调出口市场的马德里/国家注册,使被许可人出货不侵犯第三方或因不使用而失效。

二者结合

守纪的外国品牌路径:

  1. 取得稳固的中国注册作为基础商标(并实际使用)。
  2. 在需要多国覆盖时经马德里向外延伸,盯紧五年中心打击窗口。
  3. 本地伙伴使用商标时,签署并备案许可,含质量控制与终止条款。
  4. 将许可的出口计划与海外注册对齐,使供应链端到端干净。

Sources

  • 马德里商标国际注册实施办法(国家知识产权局商标局):https://sbj.cnipa.gov.cn/sbj/zcwj/200904/t20090408_6471.html
  • 马德里商标国际注册(国家知识产权局商标局):https://sbj.cnipa.gov.cn/sbj/gjzc/
  • WIPO Madrid System Information Notice no. 1/2025 — China collective/certification marks requirements:https://www.wipo.int/documents/d/madrid-system/information-notices-en-2025-madrid_2025_1_e.pdf

Enforcing Your Trademark in China: From Administrative Complaints to Well-Known Mark Protection

  • Administrative complaints to local IP offices are the fastest and cheapest first strike against infringement.
    向地方知识产权局行政投诉,是对侵权最快、成本最低的第一击。
  • The 2027 Trademark Law extends cross-class well-known-mark protection to unregistered famous marks.
    2027年《商标法》将驰名商标跨类保护扩展至未注册的驰名商标。
  • Punitive damages of one to five times apply for intentional and serious infringement, with a statutory ceiling of RMB 5 million.
    故意且情节严重的侵权适用一至五倍惩罚性赔偿,法定上限为500万元。
  • Counterfeiting can trigger criminal liability, with imprisonment of up to ten years where thresholds are met.
    假冒行为可触发刑事责任,达到门槛者最高可处十年有期徒刑。
  • Customs recordal acts as the front door of the wider enforcement chain, feeding evidence to administrative and criminal tracks.
    海关备案是更广阔执法链条的前门,将证据输送至行政与刑事路径。
  • The revised law adds a public complaint channel and new penalties for misleading “trick” marks.
    修订法新增公众举报渠道,并对误导性”心机商标”设置处罚。
  • A coordinated playbook — monitor, administer, litigate, prosecute, and border-protect — maximizes leverage.
    监测、行政、诉讼、刑事、边境五位一体的协同组合拳,方能最大化维权效能。

Enforcing Your Trademark in China: From Administrative Complaints to Well-Known Mark Protection | 商标注册后的维权之路:从行政投诉到驰名商标保护

Overview

Securing a trademark registration with CNIPA is only the first half of brand protection. Once a foreign brand operates in China, it must defend that right against counterfeiters, parallel importers and local operators who free-ride on its reputation. China provides a layered enforcement toolkit: fast administrative action by market regulators, civil litigation with punitive damages, criminal prosecution for counterfeiting, and Customs border measures. The revised Trademark Law, adopted on 26 June 2026 and effective 1 January 2027, strengthens each route and is the key change foreign owners should understand. This article maps the post-registration landscape and the enforcement playbook.

Administrative enforcement

The quickest, lowest-cost route is an administrative complaint to the local market regulation administration (the IP office within the SAMR system). Under Article 60, where infringement is found the authority orders the infringer to stop and may confiscate and destroy infringing goods and the main tools used to make them.

Fines are substantial: illegal turnover above RMB 50,000 draws a fine up to five times that turnover; with no or sub-RMB 50,000 turnover, a fine up to RMB 250,000 applies. Repeat infringers within five years, or those with other serious circumstances, face heavier punishment. A seller who neither knew nor should have known, and who proves a lawful source, is merely ordered to stop selling.

Regulators act proactively: SAMR publishes representative cases. In early 2026, local offices handled SKF bearing counterfeits, Mercedes-Benz parts, and a clothing ring spanning Max Mara, Dior, LV and Chanel worth over RMB 60 million, several referred to police. A useful feature: any unit or person may now report misleading use of a registered mark, lowering the trigger threshold.

Well-known trademark protection

For a strong brand, the most powerful tool is cross-class protection of a well-known mark (驰名商标). Under Article 13(3), a mark well known to the relevant public can block registration and use of a copy, imitation or translation on dissimilar goods where this would mislead the public and risk harming the owner’s interests (anti-dilution).

The 2027 revision helps foreign brands directly: previously this defence applied only to marks registered in China. The revised Article 13 removes the “registered in China” limit, so an unregistered mark genuinely well known to the relevant Chinese public can also block preemptive registration or use on unrelated goods.

Well-known status is confirmed case-by-case and passively; the revised law even replaces “认定” (determination) with “确认” (confirmation) to curb trophy-seeking. CNIPA may confirm it in opposition, invalidation or enforcement proceedings, and a designated People’s Court may do so in unfair-competition cases. Evidence covers degree of recognition, duration and geography of use, promotion scale, prior protection records and economic indicators such as sales and market share.

Civil litigation & damages

When administration is insufficient, civil litigation recovers money. Under Article 63, damages follow this order: the right holder’s actual loss, the infringer’s unlawful gain, or a reasonable multiple of the licence fee; where none is provable, statutory damages apply.

Punitive damages of up to five times the base apply to “intentional” and “serious” infringement. The Supreme People’s Court’s 2026 interpretation (法释〔2026〕7号, effective 1 May 2026) clarifies the concepts: intent includes infringing after notice or settlement; serious circumstances include re-offending after penalties or infringing as a business. Statutory compensation cannot be the punitive base; the total is capped at five times the base, with reasonable costs (legal fees, notarisation) separate.

The 2027 Law raises the statutory ceiling to RMB 5 million and expressly includes reasonable enforcement costs, making litigation far more attractive.

Criminal enforcement

Serious counterfeiting is a crime. Article 213 of the Criminal Law punishes using an identical mark on identical goods without permission: illegal turnover of RMB 50,000 (or income RMB 30,000), or two-or-more marks with turnover RMB 30,000, is “serious” (up to three years); the “especially serious” threshold (turnover RMB 250,000 or income RMB 150,000) brings three to ten years. The 2020 Amendment XI raised the maximum from seven to ten years.

Foreign brands pursue this by reporting to the police, often using evidence from Customs or administrative raids. A conviction also supports civil damages and deters copycats.

Coordinating with customs

China Customs (GACC) runs an IP recordal system letting holders suspend infringing imports and exports. Recordal is free and online via the Customs service platform. A recorded mark is the precondition for Customs’ ex officio active protection; without it, a holder can only seek passive protection on discovering an imminent shipment.

Customs interception is the front door of the wider chain: a seized shipment yields evidence and a suspect supply chain that can go to regulators for penalties or to police for prosecution. Brands already in the administrative and civil tracks should keep a live Customs recordal so border seizures feed the playbook. (A separate article covers Customs interception; this piece focuses on the post-registration toolkit.)

2027 Trademark Law changes

The revised Law, passed 26 June 2026 and effective 1 January 2027, is the first comprehensive revision since 1983, growing from 8 chapters / 73 articles to 9 / 87. Enforcement highlights:

  • Higher punitive damages: one-to-five times for intentional and serious infringement; statutory ceiling RMB 5 million; reasonable costs recoverable.
  • Stronger well-known protection: cross-class anti-dilution now covers unregistered famous marks; confirmation replaces determination.
  • Tighter bad-faith control: “not for use and clearly exceeding normal needs” applications are refused; bad-faith applicants face warnings and fines up to RMB 100,000; complicit agencies are liable.
  • New “trick mark” penalties: misleading use draws a correction order, fines up to five times turnover (or RMB 250,000), and possible revocation; anyone may report it.
  • Agency supervision and faster procedure: agencies must file practitioner data; the opposition period shrinks from three to two months.

These shifts tilt the balance to rights holders and raise the expected cost of infringement.

Practical playbook

  1. Monitor early and continuously; the two-month opposition window demands speed.
  2. Keep proof of use — the new law allows ex officio revocation of three-year non-use marks.
  3. Start with administration: complain to the local IP office for fast seizure, confiscation and fines; use the public-report channel.
  4. Escalate to civil where value is high; claim loss or profit and plead punitive damages; recover costs.
  5. Refer counterfeiting to the police once thresholds are met.
  6. Build a well-known file so cross-class protection is ready when dilution appears.
  7. Keep Customs recordal live so border measures feed the chain.

Related reading

  • CNIPA guidance on the 2027 revision and well-known marks.
  • SAMR representative IP enforcement cases (2026).
  • SPC interpretation on punitive damages (法释〔2026〕7号).

商标注册后的维权之路:从行政投诉到驰名商标保护

概述

向国家知识产权局(CNIPA)成功注册商标,只是品牌保护的上半场,远非终点。外国品牌一旦进入中国市场开展运营,就必须准备就注册权利向各类侵权者主动维权——既包括制造、销售假冒商品的造假者,也包括未经授权转售的平行进口商,以及刻意攀附品牌商誉、制造混淆的本地经营者。中国为权利人提供了一套分层的执法救济工具箱:市场监管部门的快速行政查处、附带惩罚性赔偿的民事诉讼、针对假冒行为的刑事打击,以及海关在边境实施的扣留措施。四条路径各有侧重、相互衔接——行政重效率、民事重赔偿、刑事重惩戒、海关守国门,组合运用方能织密保护网。这种立体保护体系,正是外国品牌得以安心扎根中国市场的重要制度保障。2026年6月26日通过、2027年1月1日施行的全面修订《商标法》,强化了上述每一条路径,是外国品牌权利人最应当理解的一项关键变化。本文旨在梳理注册之后的执法格局,说明2027年修订如何系统性地提高侵权成本,并给出一套可落地的协同维权组合拳。需要强调的是,注册只是取得权利的起点,真正决定品牌价值的,是权利人能否在侵权发生时迅速、有力地作出反应——这一点对依赖商誉的外国品牌尤为关键。

行政查处

最快、成本最低的维权路线,是向地方市场监督管理部门提出行政投诉。在省市两级市场监管体系内部,设有承担知识产权执法职责的”知识产权局”。依据《商标法》第六十条,认定侵权成立的,主管机关责令侵权人立即停止,并可没收、销毁侵权商品以及主要用于制造侵权商品的工具。相比于诉讼,行政查处通常周期更短、举证负担更轻,特别适合需要迅速制止线下门店或仓储窝点售假的情形,权利人往往能在数周内见到查扣与处罚结果。

罚款力度相当可观:违法经营额五万元以上的,可处违法经营额五倍以下的罚款;没有违法经营额或不足五万元的,可处二十五万元以下的罚款。五年内实施两次以上侵权、或有其他严重情节的,应当依法从重处罚。值得注意的是,销售者如果既不知道、也不应知道所售商品侵权,且能够证明商品合法来源并说明提供者的,仅被责令停止销售,免予罚款——这体现了对善意销售者的合理保护。

行政机关还可应当事人请求,就赔偿数额进行调解;但调解协议没有强制约束力,当事人不服的仍可向人民法院起诉。这种行政调解省时省力,适合侵权规模较小、双方有和解意愿的情形,但对于恶意侵权或赔偿争议较大的案件,权利人往往仍需转向诉讼。实践中,市场监管部门主动作为:市场监管总局定期公布知识产权执法典型案例,既震慑违法者,也为同类案件提供执法尺度参考。2026年上半年,地方局办理了SKF轴承假货系列案、奔驰汽车配件案,以及横跨Max Mara、Dior、LV、Chanel、案值超过6000万元的服装售假链条,其中多起已移送公安机关刑事侦查。对外国品牌而言,另一项实用机制是:任何单位或个人现在均可就误导性使用注册商标的行为投诉、举报,这显著降低了启动行政调查的门槛起。

驰名商标保护

对于具有高知名度的强势品牌,最强武器是驰名商标的跨类保护。依据《商标法》第十三条第三款,为相关公众所熟知的商标,可以禁止他人在不相同、不相类似商品上注册、使用复制、摹仿或翻译该商标的标志,只要该使用会误导公众、并可能损害驰名商标权人的利益——此即反淡化保护。

2027年修订在对外国品牌直接有利的方向上改变了规则:在此之前,这一跨类防御仅适用于已经在中国注册的驰名商标。修订后的第十三条删除了”已在中国注册”的限制,使得即便未在中国注册、但确为相关中国公众所熟知的商标,也能阻止在不相类似商品上的抢注或使用。这使中国的保护水平更接近CPTPP等高标准国际经贸规则。

驰名商标采取”个案确认、被动保护”原则,并非一项可永久持有的称号;修订法更将”认定”改为”确认”,以抑制社会各界”求认定”的异化倾向。确认可由国家知识产权局在异议、无效宣告或执法程序中作出,也可由指定人民法院在不正当竞争案件中作出。权利人需准备的证据涵盖商标的知晓程度、使用的持续时间与地域范围、宣传的规模、既往受保护记录,以及销量、市场份额等经济指标。鉴于确认高度依赖历史使用与知名度积累,品牌应在日常经营中即系统归档广告投放、展会参与、销售数据与获奖情况,避免临时抱佛脚。

新法还增设机制:当中国企业的商标在境外被抢注时,应其请求,国家知识产权局可确认驰名状态以支援境外确权抗辩。这对管理全球商标组合的多国企业而言,同样是一项具互惠价值的安排——换言之,一家在华布局的外国企业,其中国境内的驰名证据亦可被运用于其他法域的维权,形成双向支撑。

民事诉讼与赔偿

行政手段不足以填补损失时,向人民法院提起民事诉讼是获得金钱救济的主要路径。依据第六十三条,赔偿数额按以下优先顺序计算:权利人的实际损失、侵权人的侵权获利、或许可使用费的合理倍数;三者均难以确定时,适用法定赔偿。

对于”故意”且”情节严重”的侵权,可判处最高达计算基数五倍的惩罚性赔偿。最高人民法院2026年出台的司法解释(法释〔2026〕7号,自2026年5月1日施行)细化了相关概念:故意情形包括经有效通知或达成和解后仍实施侵权、借关联公司隐匿实际控制关系等;情节严重包括受到行政或司法处罚后再犯、拒不履行保全裁定、以侵权为业等。权利人可在诉讼中灵活选择管辖法院,典型如侵权人住所地、侵权行为实施地或侵权商品储藏地法院,以便就近举证、降低跨国维权成本。该解释明确,法定赔偿不得作为惩罚性赔偿的基数;惩罚性总额上限为基数五倍,合理维权开支(如律师费、公证费)另行计算。2025年,全国法院在505件知识产权案件中适用惩罚性赔偿,判赔金额合计18亿元,彰显从严保护的取向。

2027年《商标法》进一步将法定赔偿上限提高至500万元,并明确将合理维权费用纳入赔偿框架,使民事诉讼对外国品牌更具吸引力。实务中,权利人还可请求法院责令侵权人提交与侵权相关的账簿、资料,以解决”获利难以查清”的举证难题,这对跨境企业尤为实用。

刑事打击

情节严重的假冒行为进入刑事领域。《刑法》第二百一十三条将未经许可在同一种商品上使用与其注册商标相同商标、情节严重的行为,规定为假冒注册商标罪:违法经营额达五万元(或违法所得三万元),或假冒两种以上商标且违法经营额达三万元的,属”情节严重”,处三年以下有期徒刑或者拘役,并处或单处罚金;达到”情节特别严重”门槛(违法经营额二十五万元或违法所得十五万元)的,刑期升至三年以上十年以下有期徒刑,并处罚金。2020年《刑法修正案(十一)》将最高刑期由七年提至十年。关联罪名还涵盖销售假冒注册商标的商品罪(第二百一十四条)与非法制造、销售非法制造的注册商标标识罪(第二百一十五条)。上述罪名与行政查处、海关扣留形成梯度:情节较轻的交由行政机关罚款没收,达到刑事门槛的则移送司法机关,构成完整的责任追究链条。

对外国品牌而言,刑事路径通过向公安机关报案推进,证据往往来源于海关查扣或行政查处所固定的材料。单位实施该罪的,对单位判处罚金,并对其直接负责的主管人员和其他直接责任人员依法追究刑事责任,这显著提升了组织化制假售假的成本。刑事定罪不仅可支撑后续民事赔偿请求,也能对仿冒者形成有力威慑。

与海关的衔接

中国海关(海关总署)设有知识产权备案系统,权利人可据此申请海关中止侵权进出口货物。备案免费,通过海关政务服务一体化平台在线办理。已备案商标是海关”依职权”主动保护的前提条件;未备案的权利人,仅能在发现侵权货物即将进出口时,申请”依申请”的被动保护。

海关拦截最好理解为更广阔执法链条的”前门”:一次查扣所生成的实物证据与可疑供应链线索,可以移交市场监管部门转化为行政处罚,或移交公安机关启动刑事侦查。已在行政与民事路径上活跃的品牌,应当维持有效的海关备案,使边境查扣直接汇入前述组合拳。对于在海关总署核准总担保的权利人,请求扣留涉嫌侵权商标货物时无须逐案提交担保金,可进一步降低维权成本。(海关拦截另有专文详述,本文聚焦注册后的工具箱。)

2027年《商标法》的变化

全面修订《商标法》于2026年6月26日通过、2027年1月1日施行,是1983年施行以来首次全面修订,条文由8章73条扩至9章87条。与维权直接相关的要点如下:

  • 更高惩罚性赔偿:故意且情节严重的侵权,适用一至五倍惩罚性赔偿;法定赔偿上限提至500万元;合理维权费用可获偿。
  • 更强驰名商标保护:跨类反淡化扩展至未注册的驰名商标;”确认”取代”认定”。
  • 更严恶意注册规制:以”不以使用为目的且明显超出正常生产经营需要”申请的,不予注册;恶意申请人面临警告及最高十万元罚款;协助恶意申请的商标代理机构依法担责。
  • 新增”心机商标”处罚:以误导公众方式使用注册商标的,可被责令改正、处违法经营额五倍或二十五万元罚款,并可能撤销;任何单位或个人均可举报。
  • 代理监管与程序提速:商标代理机构须报备从业人员信息;异议期由三个月缩至两个月,倒逼权利人更快监控。

这些变化整体上向权利人倾斜,实质性抬升了侵权的预期成本。对外国品牌而言,最值得关注的,是惩罚性赔偿上限与驰名商标跨类保护范围的同步扩展,以及行政查处门槛的降低——三者叠加,使”注册后维权”从被动应对转向主动布局成为可能。

实战要点

  1. 早监测、持续监测:盯紧国家知识产权局公告与市场动态;两个月的异议窗口对响应速度提出更高要求。
  2. 留存使用证据:新法赋予主管机关依职权撤销三年不使用商标的权力,企业须系统保存销售、广告与出口证据。
  3. 行政先行:向地方知识产权局投诉,争取快速查扣、没收与罚款;善用新增的公众举报渠道。
  4. 高价值案件升级至民事:主张实际损失或侵权人获利,并就故意或严重情形请求惩罚性赔偿;一并追偿维权成本。
  5. 假冒达门槛即刑事移送:海关或行政证据满足门槛时,及时转交公安机关。
  6. 构建驰名档案:平时汇集知名度证据,使淡化威胁出现时即可启动跨类保护。
  7. 维持海关备案有效:确保边境措施能够顺畅汇入更广阔的执法链条。

上述七步并非孤立动作,而应被视为一条闭环:监测发现线索,行政快速止损,民事与刑事追索赔偿与刑事责任,海关守住边境,驰名商标档案则提供跨类兜底。外国品牌宜在入境之初即建立专门的知识产权维权台账,明确各项措施的触发条件与责任部门,方能在侵权来袭时从容打出组合拳。

相关阅读

  • 国家知识产权局关于2027年《商标法》修订及驰名商标规则的指引。
  • 市场监管总局知识产权执法典型案例(2026)。
  • 最高人民法院惩罚性赔偿司法解释(法释〔2026〕7号)。
  • 海关总署知识产权海关保护备案办事指南(衔接边境维权)。

Sources

China’s fully revised Trademark Law (effective 1 January 2027): what foreign brand owners should do now

  • China’s Trademark Law has been fully revised for the first time since 1983, adopted on 26 June 2026 (Presidential Order No. 77) and effective 1 January 2027.
    中国《商标法》自1983年施行以来首次全面修订,于2026年6月26日修订通过(主席令第七十七号),自2027年1月1日起施行。
  • The statute grows from 8 chapters / 73 articles to 9 chapters / 87 articles, with a new dedicated chapter on registration conditions.
    法律体例由原8章73条扩为9章87条,新增专章集中规定商标注册条件。
  • Dynamic marks and their combinations are newly registrable, and internet-based use now counts as trademark use.
    可注册要素新增动态标志及其组合,通过互联网等信息网络实施的使用行为明确属于商标的使用。
  • Foreign applicants with no domicile or business presence in China must file through a duly established trademark agent.
    在中国没有经常居所或营业所的外国人、外国企业,申请商标注册和办理其他商标事宜应当委托依法设立的商标代理机构。
  • Bad-faith filing is pushed forward in the enforcement chain: a warning plus a fine up to RMB 100,000 for malicious applications causing adverse impact.
    恶意申请惩戒关口前移:存在恶意申请注册行为造成不良影响的,由负责商标执法的部门给予警告,可以并处10万元以下罚款。
  • Core timelines are codified: 9-month examination, 2-month opposition, 9+3-month review, 10-year term, 12-month renewal window plus 6-month grace.
    关键时限入法:审查9个月、异议期2个月、复审9个月可延长3个月、有效期10年、续展期12个月并设6个月宽展期。
  • Foreign brand owners should audit portfolios, tighten agent and distributor contracts, and plan refilings before the 1 January 2027 transition.
    外资品牌方应审计商标组合、收紧代理与经销商合同条款,并在2027年1月1日过渡前规划重新布局与补充申请。

China’s fully revised Trademark Law (effective 1 January 2027): what foreign brand owners should do now | 中国《商标法》首次全面修订(2027年1月1日施行):外资品牌方现在应当做什么

Overview: A Once-in-a-Generation Rewrite

For any foreign enterprise building or defending a brand in China, the Trademark Law is the backbone statute. On 26 June 2026, the 23rd Session of the Standing Committee of the 14th National People’s Congress adopted a comprehensive revision by Presidential Order No. 77, effective 1 January 2027. The law was first enacted in 1983; the four prior changes (1993, 2001, 2013, 2019) were partial corrections. The 2026 revision is the first full revision in over four decades, expanding from 8 chapters / 73 articles to 9 chapters / 87 articles and adding a dedicated chapter on registration conditions.

The Legal Basis and the Three Significances

The operative instrument is the Trademark Law of the PRC (2026 Revision), revised and adopted on 26 June 2026, promulgated by Presidential Order No. 77, effective 1 January 2027. The NPC frames the revision around three points: implementing the Party and state IP strategy; answering real-world pathologies — bad-faith filing, hoarding of idle marks, improper use, weak penalties, over-enforcement, agency disorder; and systematising more than forty years of practice.

A New Structure: From 8/73 to 9/87

The statute moves from 8 chapters / 73 articles to 9 chapters / 87 articles. A new Chapter II, “Conditions for Trademark Registration,” consolidates absolute grounds, relative prior rights, distinctiveness and functionality exclusions into one chapter, separating substantive conditions from examination procedure. Institutional language is unified: “Trademark Office” and “Trademark Review and Adjudication Board” become the single “trademark administrative department of the State Council” (the CNIPA system); “administrative departments for industry and commerce” become “departments responsible for trademark enforcement.”

New Registrable Subject Matter and the Internet “Use” Rule

To keep pace with digital dissemination, the revision adds dynamic marks and their combinations as registrable subject matter. The functionality bar remains: a sign consisting solely of a shape, colour combination, sound or dynamic effect dictated by the nature of goods, needed for a technical effect, or giving substantial value shall not be registered (Article 18). Article 2 clarifies that use through the internet or other information networks is “use of a trademark” — grounding online presence on e-commerce and social platforms as genuine use for defence, non-use cancellation and opposition.

Good Faith, Foreign Agents and Madrid

Article 9 makes the good-faith principle explicit: filing and use shall not abuse rights to the detriment of national interest, public interest or others’ lawful rights. Article 11 requires foreigners or foreign enterprises with no habitual residence or business premises in China to entrust a duly established trademark agency for filing and other matters. Article 12 routes international registration through the Madrid system under China’s treaties, with rules set by the State Council. Choose agents carefully and define their mandate in writing.

Bad Faith, Well-Known Marks and Squatting

Article 19 refuses registration of applications not intended for use and clearly exceeding normal needs, and bars fraud or other improper means. The penalty gateway moves forward: malicious filing causing adverse impact draws a warning and a fine up to RMB 100,000 from the enforcement department. Article 21 refines well-known mark protection and shifts “recognising” to “confirming” a mark as well known, closer to international rules. Articles 22 and 24 target agent, representative and relationship-based squatting — opposable only if the owner proves prior use and the relationship. Article 25 bars agencies from registering any mark other than for their own services.

Multi-Class, Priority and Codified Timelines

Article 26 allows a single application covering multiple classes. Article 29 grants a 6-month foreign priority (written declaration plus copy within 3 months); Article 30 adds a 6-month exhibition priority. Core clocks are now statutory:

StagePeriod
Examination of an application9 months (Art. 32)
Opposition period2 months (Art. 36)
Refusal review9 months, +3 months (Art. 37)
Opposition decision12 months, +6 months (Art. 38)
Registration term10 years (Art. 43)
Renewal12 months before expiry; 6-month grace (Art. 44)

New Absolute Grounds and Division of Duties

Article 15 bars marks identical or similar to the name, flag, emblem or medals of the Communist Party of China, or to landmark elements of its theoretical achievements or historical events. Article 16 bars county-level or higher place names and public foreign place names (except other meaning or collective/certification marks; existing registrations survive). The trademark department of the State Council (CNIPA) handles nationwide registration; local trademark-administration and enforcement departments (market-supervision system) act locally, with statutory information sharing and coordination.

Implementation and the Transition Window

The revised statute takes effect 1 January 2027, but the enforcement machinery is being built now. The national IP administration is advancing the supporting revision of the Trademark Law Implementing Regulations to detail standards and procedure, updating the Trademark Examination and Adjudication Guidelines, and studying old-new law transitional rules covering applicable law during the switchover and filing conditions for dynamic marks. Foreign owners should treat the window before 1 January 2027 as the low-friction period to clean up portfolios, fix agent mandates and pre-file marks that may face the new absolute grounds.

What Foreign Brand Owners Should Do Now

  1. Audit the portfolio against new grounds (political, geographic, functional) before 1 January 2027.
  2. Confirm agent appointments in writing; the agent cannot register your marks for itself (Art. 11, 25).
  3. Tighten distributor and partner contracts with evidence clauses proving prior use and the relationship (Art. 22, 24).
  4. Calendar priority and renewal clocks; remind 12 months before expiry to avoid grace risk.
  5. Plan multi-class and dynamic-mark filings where distinctive (Art. 26, dynamic marks).
  6. Sequence Madrid and direct filings to preserve the 6-month priority.
  7. Expect two-track enforcement through both IP-administration and market-supervision systems.

Related Reading

Foreign-brand registration workflow and the dedicated anti-squatting playbook are covered in separate articles on this site; this piece is the revision briefing plus the action list.


中国《商标法》首次全面修订(2027年1月1日施行):外资品牌方现在应当做什么

概览:一代人一次的系统性重写

对任何在中国创建或守护品牌的外国企业,《商标法》是基础性法律。2026年6月26日,第十四届全国人大常委会第二十三次会议以主席令第七十七号修订通过,自2027年1月1日起施行。该法1983年首次施行,此前四次变动(1993、2001、2013、2019)均为局部修正;2026年修订是四十多年来首次全面修订,文本由8章73条扩至9章87条,新增专章规定注册条件。

法律依据与三大意义

现行依据是《中华人民共和国商标法(2026年修订)》,2026年6月26日修订通过,主席令第七十七号公布,自2027年1月1日施行。全国人大将修订归纳为三点:贯彻党和国家知识产权战略;回应恶意申请、囤积闲置、不当使用、惩戒不足、过度维权、代理失序等现实病症;系统总结四十多年实践经验。

新结构:从8章73条到9章87条

法律由8章73条增至9章87条,新增”第二章 商标注册的条件”,将绝对禁止事由、相对在先权益、显著特征与功能性排除集中成章,使实体条件与审查程序分离。机构称谓统一:原”商标局””商标评审委员会”统称”国务院商标管理部门”(即国家知识产权局/CNIPA体系);原”工商行政管理部门”改为”负责商标执法的部门”。

新增要素与互联网”使用”规则

为顺应数字化传播,修订新增”动态标志及其组合”作为可注册要素。功能性门槛保留:仅由商品性质决定、为技术效果所必需或使商品具实质性价值的形状、颜色组合、声音、动态效果,不得注册(第18条)。第2条明确,通过互联网等信息网络实施的使用属于商标的使用——使电商平台、社交媒体上的线上 presence 可作为抗辩、对抗三年不使用撤销及异议中的真实使用依据。

诚信、外国代理与马德里

第9条使诚信原则显性化:申请与使用不得滥用权利损害国家利益、公共利益或他人合法权益。第11条要求在中国没有经常居所或营业所的外国人、外国企业,应当委托依法设立的商标代理机构办理申请及其他事宜。第12条依我国缔结或参加的国际条约(马德里体系)办理商标国际注册,具体办法由国务院规定。应审慎选择代理机构并以书面界定权限。

恶意申请、驰名商标与抢注

第19条对不以使用为目的且明显超出正常需要、或以欺骗等不正当手段的申请不予注册。处罚关口前移:恶意申请注册造成不良影响的,由负责商标执法的部门给予警告,可以并处10万元以下罚款。第21条细化驰名商标保护,将”认定”调整为”确认”,更贴近国际规则。第22条、第24条针对代理人、代表人及关系型抢注——以自己名义抢注或明知在先使用仍抢注的,异议后不予注册,但前提是企业证明在先使用及关系。第25条禁止代理机构注册自身服务以外的商标。

多类申请、优先权与入法时限

第26条允许一份申请覆盖多个类别。第29条给予自外国首次申请起6个月优先权(须书面声明并于3个月内提交副本);第30条新增展会优先权6个月。关键时限现已入法:

阶段期限
申请实质审查9个月(第32条)
异议期2个月(第36条)
驳回复审9个月,可延长3个月(第37条)
异议审查12个月,可延长6个月(第38条)
注册有效期10年(第43条)
续展期满前12个月;宽展6个月(第44条)

新增绝对禁注与职责分工

第15条禁止同中国共产党名称、党旗、党徽、勋章或重要理论成就、历史事件相关标志性要素相同近似的标志。第16条禁止县级以上行政区划名称及公众知晓的外国地名(有其他含义或作为集体/证明商标组成部分除外;已注册继续有效)。国务院商标管理部门(CNIPA)负责全国注册管理;地方商标管理与执法部门(市场监管体系)属地执法,并负法定信息共享与协调义务。

配套实施与过渡窗口

修订后法律自2027年1月1日施行,但执法机制正在当下搭建。国家知识产权体系正推进《商标法实施条例》配套修改以细化标准与程序,更新《商标审查审理指南》,并研究涵盖切换期法律适用与动态标志申请条件的旧法新法衔接规则。外国品牌方应将2027年1月1日前视为低摩擦窗口,清理组合、补正代理授权,并对可能触及新绝对禁注事由的商标提前申请。

外资品牌方现在应当做什么

  1. 按新禁注事由审计组合(政治、地理、功能性),在2027年1月1日前完成。
  2. 书面确认代理委托;代理机构不得自注你的商标(第11、25条)。
  3. 收紧经销商与伙伴合同,植入证明在先使用及关系的证据条款(第22、24条)。
  4. 对优先权与续展排期;期满前12个月提醒,规避宽展风险。
  5. 规划多类与动态标志申请(第26条及动态标志),在具显著性处布局。
  6. 安排马德里与直接申请次序,保全6个月优先权。
  7. 预期双线执法,知识产权行政与市场监管两线均可行动。

延伸阅读

外国品牌商标注册流程与恶意抢注专文攻略本站另有专文;本文为修订简报加行动清单。

Sources

Patent Open Licensing and Administrative Adjudication: Faster IP Enforcement for Foreign Firms in China (2026)

  • China’s 2020 Patent Law reform introduced an *open licensing* system: a patentee may declare a patent openly licensable at a published royalty, and any party can obtain a licence simply by paying and notifying.
    中国 2020 年专利法修订引入了*开放许可*制度:专利权人可声明以公布的费率开放许可,任何主体付费并通知即可获得实施许可。
  • The CNIPA’s 2024 *Measures for Mediating Open-Licensing Disputes* (Order No. 590) give patentees and licensees a fast, specialised channel to resolve royalty and term disputes.
    国家知识产权局 2024 年《专利开放许可实施纠纷调解工作办法(试行)》(第590号)为专利权人与被许可人提供了快速、专门的渠道,解决使用费与期限等纠纷。
  • During the open-licensing period, the patentee’s annual fees are reduced or waived, lowering the cost of keeping patents alive while broadening their commercial use.
    开放许可实施期间,专利权人年费相应减免,在降低维持成本的同时拓宽了专利的商业运用。
  • For infringement, administrative adjudication by the IP office remains a fast alternative to court: it can order cessation and determine damages, with decisions enforceable through the courts.
    就侵权而言,知识产权局的行政裁决仍是法院之外的快速选项:可责令停止侵权并确定赔偿,决定经法院强制执行。
  • Foreign firms should weigh open licensing as a monetisation and defensiveness tool, and use administrative adjudication where speed and lower cost matter.
    外资企业应把开放许可视为变现与防御工具,并在重视速度与低成本时运用行政裁决。
  • Documentation is decisive: a registered open-licensing declaration and a clear licence record are what make the system work in practice.
    文档至关重要:已登记的开放许可声明与清晰的许可记录,是制度实际运转的关键。

Patent Open Licensing and Administrative Adjudication: Faster IP Enforcement for Foreign Firms in China (2026) | 专利开放许可与行政裁决:外资企业在中国更快的知识产权维权(2026)

Why this matters now

China is the world’s largest patent filing jurisdiction, and for foreign-invested enterprises (FIEs) the question is no longer just “how do I get a patent” but “how do I use it and enforce it efficiently”. Two instruments have matured since the 2020 Patent Law amendment: open licensing, which turns a granted patent into a standardised, low-friction licence, and administrative adjudication of infringement, which offers a faster, cheaper route to relief than litigation.

This article explains both, how they work in practice, and what FIEs should consider. It pairs with our patent and IP-enforcement coverage.

Open licensing: the basics

Under Articles 50–52 of the Patent Law (as amended in 2020), a patentee may voluntarily declare, in writing to the China National Intellectual Property Administration (CNIPA), a willingness to licence any unit or individual, stating the royalty payment method and standard. CNIPA announces the declaration. Any party wishing to use the patent notifies the patentee in writing and pays the published royalty — and obtains a licence. During the open-licensing period, the patentee’s annual fees are correspondingly reduced or waived.

Open licensing cannot be exclusive or sole; the patentee may still grant ordinary licences by negotiation, but not exclusive or sole rights over the open-licensed patent.

Resolving open-licensing disputes

Because open licensing is standardised, most disputes are about the royalty standard and payment method, the effective date, and the licence term. CNIPA’s 2024 *Measures for Mediating Open-Licensing Disputes (Trial)* (Order No. 590) provide a dedicated mediation channel:

  • A party applies in writing; CNIPA decides on acceptance within five working days.
  • Mediation is completed within 30 working days (extendable by mutual consent).
  • Outcomes are recorded in a mediation agreement that takes effect upon signing.

The measures implement the Patent Law’s instruction that open-licensing disputes may be mediated by the patent administration or taken to court.

Administrative adjudication of infringement

For patent infringement, the IP office (CNIPA locally, or the municipal IP administration) can, at a party’s request, adjudicate: if infringement is found, it may order cessation and mediate damages. Decisions are administratively enforceable, and persistent non-compliance can be referred to the courts for enforcement. This route is typically faster and less costly than a full court action, though parties retain the right to litigate.

The dual track — administrative and judicial — is the backbone of China’s “double-track” IP protection system, reinforced by the 2024 *Implementation Plan for Building an IP Protection System*.

What FIEs should consider

  1. Monetisation: patents that are licensed little but maintained expensively are candidates for open licensing — the fee reduction offsets the cost, and licensing broadens commercial value.
  2. Defensiveness: a broad open-licensing declaration can pre-empt royalty disputes and demonstrate good-faith licensing.
  3. Speed: for clear infringement, administrative adjudication can stop the conduct quickly while a damages figure is worked out.
  4. Evidence: keep the registered declaration, licence records, and correspondence; they are the operating proof the system relies on.

Practical steps

  • Assess your portfolio for patents suited to open licensing (stable, broadly useful, low maintenance value otherwise).
  • Register the declaration with CNIPA and publish the royalty terms clearly.
  • For infringement, choose administrative adjudication where speed matters and court where precedent or higher damages are the priority.
  • Integrate open licensing and enforcement into the China IP strategy rather than treating them as isolated events.

Common pitfalls to avoid

Two mistakes recur. First, treating open licensing as a one-click revenue tap: a declaration must state a clear, published royalty, and the patent must be in good standing — an expired or invalidated patent cannot be licensed this way, and an annual-fee lapse forfeits the fee reduction. Second, assuming administrative adjudication replaces litigation: it is fast for cessation orders, but damages quantified through the IP office are often modest, and a court action may still be needed for full recovery. A further point: open licensing does not bar the patentee from enforcing against infringers who never took a licence — the declarant retains full infringement remedies. FIEs should calendar renewal deadlines and keep the declaration, licence notices, and any mediation records in one file so the system works as designed.

Related reading

  • Patent protection and administrative enforcement in China.
  • Customs IP protection for foreign brands.
  • The Hague Agreement and industrial-design protection.

专利开放许可与行政裁决:外资企业在中国更快的知识产权维权(2026)/ Patent Open Licensing and Administrative Adjudication: Faster IP Enforcement for Foreign Firms in China (2026)

为何重要

中国是全球最大的专利受理国,对 ded 外商投资企业而言,问题已不只是”如何获得专利”,而是”如何高效运用与维权”。自 2020 年专利法修订以来,两项工具日趋成熟:开放许可将已授权专利转为标准化、低摩擦的许可;侵权行政裁决提供比诉讼更快、更省的救济路径。

本文说明二者及其实践运作,以及外资企业应考虑的事项,与本站专利与知识产权执法专题相互呼应。

开放许可:基础

依 2020 年修订后《专利法》第五十至五十二条,专利权人可书面自愿向国家知识产权局声明愿意许可任何单位或个人实施其专利,并明确许可使用费支付方式与标准,由国知局公告。任何有意愿实施的单位或个人书面通知专利权人并依公告支付使用费后,即获得实施许可。开放许可实施期间,专利权人年费相应减免。

开放许可不得为独占或排他许可;专利权人仍可与被许可人协商给予普通许可,但不得就该专利给予独占或排他许可。

开放许可纠纷的化解

开放许可标准化后,多数纠纷集中于使用费标准与支付方式、生效时间、许可期限。国家知识产权局 2024 年《专利开放许可实施纠纷调解工作办法(试行)》(第590号)提供了专门调解渠道:

  • 当事人书面申请;国知局于 5 个工作日内决定是否受理。
  • 调解自受理之日起 30 个工作日内完成(经双方同意可延长)。
  • 达成协议的,制作调解协议书,自签字盖章之日起生效。

该办法落实了专利法关于开放许可纠纷可由专利行政部门调解或向人民法院起诉的规定。

侵权行政裁决

就专利侵权,知识产权部门(地方知识产权局或市知识产权主管部门)可依请求作出行政裁决:认定侵权成立的,可责令立即停止侵权并组织赔偿调解。裁决具行政执行力,拒不履行的可提请法院强制执行。该路径通常快于、廉于完整诉讼,但当事人仍保留诉权。

行政与司法并行的”双轨制”是中国知识产权保护体系的骨架,并由 2024 年《知识产权保护体系建设工程实施方案》进一步强化。

外资企业应考虑的事项

  1. 变现:少有许可却维持昂贵的专利,是开放许可的候选——年费减免抵销成本,许可拓宽商业价值。
  2. 防御:广泛的开放许可声明可预先化解费率争议,并展示善意许可。
  3. 速度:对明显侵权,行政裁决可快速制止行为,同时核算赔偿数额。
  4. 证据:保留登记声明、许可记录与往来函件,它们是制度运转所依赖的操作凭证。

实务步骤

  • 评估组合中适合开放许可的专利(稳定、通用、原本维持价值低)。
  • 向国知局登记声明并清晰公告费率条款。
  • 侵权时,在重视速度时选行政裁决,在追求先例或更高赔偿时选法院。
  • 将开放许可与维权纳入中国知识产权战略,而非孤立事件。

应避免的常见误区

两类错误反复出现。其一,把开放许可当作一键增收:声明须载明清晰、公开的费率,且专利须维持有效——过期或被宣告无效的专利无法以此方式许可,年费断缴也将丧失减免。其二,误以为行政裁决可替代诉讼:其对责令停止侵权快捷,但经知识产权部门核定的赔偿往往有限,全额追偿仍可能需诉至法院。另一点:开放许可不妨碍专利权人对从未取得许可的侵权者维权——声明人保留完整的侵权救济。外资企业应将年费续展截止日纳入日历,并将声明、许可通知与任何调解记录归于一档,使制度按设计运转。

延伸阅读

  • 中国的专利保护与行政执法。
  • 针对外资品牌的海关知识产权保护。
  • 海牙协定与工业品外观设计保护。

Sources

  • 国家知识产权局:第590号公告《专利开放许可实施纠纷调解工作办法(试行)》— https://www.gov.cn/zhengce/zhengceku/202407/content_6963549.htm
  • 国家知识产权局:《中华人民共和国专利法》修改决定(2020),开放许可制度(第五十条至第五十二条)— https://www.cnipa.gov.cn/art/2020/10/18/art_53_153525.html
  • 国家知识产权局:《专利开放许可实施纠纷调解工作办法(试行)》解读 — https://www.cnipa.gov.cn/art/2024/7/15/art_66_193750.html